Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP) by United States. Advisory Committee on Immunization Practices. et al.
Morbidity and Mortality Weekly Report
Recommendations and Reports July 28, 2006 / Vol. 55 / No. RR-10
department of health and human services
Centers for Disease Control and Prevention
Prevention and Control of Influenza
Recommendations of the Advisory Committee
on Immunization Practices (ACIP)
MMWR
Centers for Disease Control and Prevention
Julie L. Gerberding, MD, MPH
Director
Tanja Popovic, MD, PhD
(Acting) Chief Science Officer
James W. Stephens, PhD
(Acting) Associate Director for Science
Steven L. Solomon, MD
Director, Coordinating Center for Health Information and Service
Jay M. Bernhardt, PhD, MPH
Director, National Center for Health Marketing
Judith R. Aguilar
(Acting) Director, Division of Health Information Dissemination (Proposed)
Editorial and Production Staff
Mary Lou Lindegren, MD
Editor, MMWR Series
Frederic E. Shaw, MD, JD
Guest Editor, MMWR Series
Suzanne M. Hewitt, MPA













William L. Roper, MD, MPH, Chapel Hill, NC, Chairman
Virginia A. Caine, MD, Indianapolis, IN
David W. Fleming, MD, Seattle, WA
William E. Halperin, MD, DrPH, MPH, Newark, NJ
Margaret A. Hamburg, MD, Washington, DC
King K. Holmes, MD, PhD, Seattle, WA
Deborah Holtzman, PhD, Atlanta, GA
John K. Iglehart, Bethesda, MD
Dennis G. Maki, MD, Madison, WI
Sue Mallonee, MPH, Oklahoma City, OK
Stanley A. Plotkin, MD, Doylestown, PA
Patricia Quinlisk, MD, MPH, Des Moines, IA
Patrick L. Remington, MD, MPH, Madison, WI
Barbara K. Rimer, DrPH, Chapel Hill, NC
John V. Rullan, MD, MPH, San Juan, PR
Anne Schuchat, MD, Atlanta, GA
Dixie E. Snider, MD, MPH, Atlanta, GA
John W. Ward, MD, Atlanta, GA
The MMWR series of publications is published by the Coordinating
Center for Health Information and Service, Centers for Disease
Control and Prevention (CDC), U.S. Department of Health and
Human Services, Atlanta, GA 30333.
Suggested Citation: Centers for Disease Control and Prevention.
[Title]. MMWR 2006;55(No. RR-#):[inclusive page numbers].
CONTENTS
Introduction ........................................................................ 1
Primary Changes and Updates in the Recommendations .. 2
Influenza and Its Burden ................................................... 3
Options for Controlling Influenza ..................................... 4
Comparison of LAIV with Inactivated Influenza Vaccine .... 6
Cost-Effectiveness of Influenza Vaccine ............................ 8
Vaccination Coverage Levels ............................................ 9
Recommendations for Using Inactivated and Live,
Attenuated Influenza Vaccines ....................................... 11
Target Groups for Vaccination ........................................ 11
Additional Information Regarding Vaccination
of Specific Populations ................................................ 12
Inactivated Influenza Vaccine Recommendations ............ 14
Live, Attenuated Influenza Vaccine Recommendations .... 18
Recommended Vaccines for Different Age Groups .......... 20
Influenza Vaccine Supply and Timing of Annual
Influenza Vaccination .................................................. 21
Strategies for Implementing Vaccination
Recommendations in Health-Care Settings ................. 22
Future Directions for Research and Recommendations
Related to Influenza Vaccine ....................................... 24
Recommendations for Using Antiviral Agents for Influenza . 24
Antiviral Agents for Influenza ......................................... 24
Role of Laboratory Diagnosis .......................................... 24
Antiviral Drug-Resistant Strains of Influenza Virus .......... 25




Side Effects and Adverse Reactions ................................. 29
Use During Pregnancy .................................................... 29
Drug Interactions ............................................................ 30
Information Regarding the Vaccines for Children Program.. 30
Sources of Information Regarding Influenza
and Its Surveillance........................................................ 30
Reporting of Adverse Events Following Vaccination ........... 30
Additional Information Regarding Influenza Virus
Infection Control Among Specific Populations ................ 30
References ........................................................................ 31
Vol. 55 / RR-10 Recommendations and Reports 1
The material in this report originated in the National Center for
Immunization and Respiratory Diseases (proposed), Anne Schuchat,
MD, Director; Influenza Division (proposed), Nancy Cox, PhD,
(Acting) Director; and Immunization Services Division, Lance
Rodewald, Director.
Corresponding preparer: Joseph Bresee, MD, Influenza Division,
National Center for Immunization and Respiratory Diseases, 1600 Clifton
Road, N.E., MS A-32, Atlanta, GA 30333. Telephone: 404-639-3747;
Fax: 404-639-3866; E-mail: jbresee@cdc.gov.
Prevention and Control of Influenza
Recommendations of the Advisory Committee
on Immunization Practices (ACIP)
Prepared by
Nicole M. Smith, PhD1
 Joseph S. Bresee, MD1
 David K. Shay, MD1
 Timothy M. Uyeki, MD1
Nancy J. Cox, PhD1
Raymond A. Strikas, MD2
1Influenza Division (proposed)
2Immunization Services Division
National Center for Immunization and Respiratory Diseases (proposed)
Summary
This report updates the 2005 recommendations by the Advisory Committee on Immunization Practices (ACIP) regarding the
use of influenza vaccine and antiviral agents (CDC. Prevention and control of influenza: recommendations of the Advisory
Committee on Immunization Practices [ACIP]. MMWR 2005;54[No. RR-8]:1–44). The 2006 recommendations include
new and updated information. Principal changes include 1) recommending vaccination of children aged 24–59 months and
their household contacts and out-of-home caregivers against influenza; 2) highlighting the importance of administering 2 doses
of influenza vaccine for children aged 6 months–<9 years who were previously unvaccinated; 3) advising health-care providers,
those planning organized campaigns, and state and local public health agencies to a) develop plans for expanding outreach and
infrastructure to vaccinate more persons than the previous year and b) develop contingency plans for the timing and prioritization
of administering influenza vaccine, if the supply of vaccine is delayed and/or reduced; 4) reminding providers that they should
routinely offer influenza vaccine to patients throughout the influenza season; 5) recommending that neither amantadine nor
rimantadine be used for the treatment or chemoprophylaxis of influenza A in the United States until evidence of susceptibility to
these antiviral medications has been re-established among circulating influenza A viruses; and 6) using the 2006–07 trivalent
influenza vaccine virus strains: A/New Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malay-
sia/2506/2004-like antigens. For the A/Wisconsin/67/2005 (H3N2)-like antigen, manufacturers may use the antigenically
equivalent A/Hiroshima/52/2005 virus; for the B/Malaysia/2506/2004-like antigen, manufacturers may use the antigenically
equivalent B/Ohio/1/2005 virus. A link to this report and other information can be accessed at http://www.cdc.gov/flu.
Introduction
In the United States, epidemics of influenza typically occur
during the winter months and have been associated with an
average of approximately 36,000 deaths per year in the United
States during 1990–1999 (1). Influenza viruses cause disease
among all age groups (2–4). Rates of infection are highest among
children, but rates of serious illness and death are highest among
persons aged >65 years, children aged <2 years, and persons of
any age who have medical conditions that place them at in-
creased risk for complications from influenza (2,5–7).
Influenza vaccination is the primary method for prevent-
ing influenza and its severe complications. As indicated in
this report from the Advisory Committee on Immunization
Practices (ACIP), annual influenza vaccination is now rec-
ommended for the following groups (Box):
• persons at high risk for influenza-related complications
and severe disease, including
— children aged 6–59 months,
— pregnant women,
— persons aged >50 years,
— persons of any age with certain chronic medical con-
ditions; and
• persons who live with or care for persons at high risk,
including
— household contacts who have frequent contact with
persons at high risk and who can transmit influenza to
those persons at high risk and
— health-care workers.
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Vaccination might prevent hospitalization and death among
persons at high risk and might also reduce influenza-related
respiratory illnesses and physician visits among all age groups,
prevent otitis media among children, and decrease work ab-
senteeism among adults (8–18). Although influenza vaccina-
tion levels increased substantially during the 1990s, further
improvements in vaccination coverage levels are needed, es-
pecially among persons aged <65 years with known risk fac-
tors for influenza complications; among blacks and Hispanics
aged >65 years; among children aged 6–23 months; and among
health-care workers. ACIP recommends using strategies to
improve vaccination levels, including using reminder/recall
systems and standing orders programs (19–22). Although
influenza vaccination remains the cornerstone for the control
of influenza, information on antiviral medications also is pre-
sented in this report because these agents are an important
adjunct to vaccine.
Primary Changes and Updates in the
Recommendations
The 2006 recommendations include six principal changes
or updates:
• ACIP recommends that healthy children aged 24–59
months and their household contacts and out-of-home
caregivers be vaccinated against influenza (see Target
Groups for Vaccination). This change extends the rec-
ommendations for vaccination of children so that all chil-
dren aged 6–<59 months receive annual vaccination.
• ACIP emphasizes that all children aged 6 months–<9 years
who have not been previously vaccinated at any time with
either live, attenuated influenza vaccine (LAIV) or triva-
lent inactivated influenza vaccine (TIV) should receive 2
doses of vaccine. Those children aged 6 months–<9 years
who receive TIV should have a booster dose of TIV ad-
ministered >1 month after the initial dose, before the onset
of influenza season, if possible. Those children aged 5–
<9 years who receive LAIV should have a second dose of
LAIV 6–10 weeks after the initial dose, before the influ-
enza season, if possible. If a child aged 6 months–<9 years
received influenza vaccine for the first time during a pre-
vious season but did not receive a second dose of vaccine
within the same season, only 1 dose of vaccine should be
administered this season (see Efficacy and Effectiveness
of Inactivated Influenza Vaccine, Children; TIV Dosage;
and LAIV Dosage and Administration).
• To ensure optimal use of available doses of influenza vac-
cine, projected to be approximately 100 million doses,
health-care providers, those planning organized campaigns,
and state and local public health agencies should 1) de-
velop plans for expanding outreach and infrastructure to
vaccinate more persons than during the previous year and
2) develop contingency plans for the timing and
prioritization of administering influenza vaccine, if the
supply of vaccine is delayed and/or reduced because of the
complexity of the production process (see Influenza Vac-
cine Supply and Timing of Annual Influenza Vaccination).
• ACIP emphasizes that influenza vaccine should continue
to be offered throughout the influenza season even after
influenza activity has been documented in a community.
In addition, ACIP encourages all community vaccina-
tors and public health agencies to schedule clinics that
serve target groups and to help extend the routine vacci-
nation season by offering at least one vaccination clinic
in December (see Influenza Vaccine Supply and Timing
of Annual Influenza Vaccination).
• ACIP recommends that neither amantadine nor
rimantadine be used for the treatment or chemoprophy-
BOX. Persons for whom annual vaccination is recommended
• Children aged 6–59 months;
• Women who will be pregnant during the influenza season;
• Persons aged >50 years;
• Children and adolescents (aged 6 months–18 years) who
are receiving long-term aspirin therapy and, therefore,
might be at risk for experiencing Reye syndrome after
influenza infection;
• Adults and children who have chronic disorders of the
pulmonary or cardiovascular systems, including asthma
(hypertension is not considered a high-risk condition);
• Adults and children who have required regular medical
follow-up or hospitalization during the preceding year
because of chronic metabolic diseases (including diabe-
tes mellitus), renal dysfunction, hemoglobinopathies,
or immunodeficiency (including immunodeficiency
caused by medications or by human immunodeficiency
virus);
• Adults and children who have any condition (e.g., cog-
nitive dysfunction, spinal cord injuries, seizure disorders,
or other neuromuscular disorders) that can compromise
respiratory function or the handling of respiratory secre-
tions, or that can increase the risk for aspiration;
• Residents of nursing homes and other chronic-care fa-
cilities that house persons of any age who have chronic
medical conditions;
• Persons who live with or care for persons at high risk
for influenza-related complications, including healthy
household contacts and caregivers of children aged 0–59
months; and
• Health-care workers.
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laxis of influenza A in the United States because of recent
data indicating widespread resistance of influenza virus
to these medications (23,24). Until susceptibility to
adamantanes has been re-established among circulating
influenza A viruses, oseltamivir or zanamivir may be pre-
scribed if antiviral treatment or chemoprophylaxis of in-
fluenza is indicated (see Recommendations for Using
Antiviral Agents for Influenza).
• The 2006–07 trivalent vaccine virus strains are A/New
Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005
(H3N2)-like, and B/Malaysia/2506/2004-like antigens.
For the A/Wisconsin/67/2005 (H3N2)-like antigen,
manufacturers may use the antigenically equivalent
A/Hiroshima/52/2005 virus; for the B/Malaysia/2506/
2004-like antigen, manufacturers may use the antigeni-
cally equivalent B/Ohio/1/2005 virus (see Influenza Vac-
cine Composition).
Influenza and Its Burden
Biology of Influenza
Influenza A and B are the two types of influenza viruses
that cause epidemic human disease (25). Influenza A viruses
are further categorized into subtypes on the basis of two sur-
face antigens: hemagglutinin and neuraminidase. Influenza B
viruses are not categorized into subtypes. Since 1977, influ-
enza A (H1N1) viruses, influenza A (H3N2) viruses, and in-
fluenza B viruses have circulated globally. In 2001, influenza
A (H1N2) viruses that probably emerged after genetic
reassortment between human A (H1N1) and A (H3N2) vi-
ruses began circulating widely. Both influenza A and B vi-
ruses are further separated into groups on the basis of antigenic
characteristics. New influenza virus variants result from fre-
quent antigenic change (i.e., antigenic drift) resulting from
point mutations that occur during viral replication. Influ-
enza B viruses undergo antigenic drift less rapidly than influ-
enza A viruses.
Immunity to the surface antigens, particularly the hemag-
glutinin, reduces the likelihood of infection and severity of
disease if infection occurs (26). Antibody against one influ-
enza virus type or subtype confers limited or no protection
against another type or subtype of influenza. Furthermore,
antibody to one antigenic variant of influenza virus might
not completely protect against a new antigenic variant of the
same type or subtype (27). Frequent development of anti-
genic variants through antigenic drift is the virologic basis for
seasonal epidemics and the reason for the usual incorpora-
tion of one or more new strains in each year’s influenza vac-
cine. More dramatic antigenic changes, or shifts, occur less
frequently and can result in the emergence of a novel influ-
enza virus with the potential to cause a pandemic.
Clinical Signs and Symptoms of Influenza
Influenza viruses are spread from person to person, prima-
rily through respiratory droplet transmission (e.g., when an
infected person coughs or sneezes in close proximity to an
uninfected person) (25). The typical incubation period for
influenza is 1–4 days, with an average of 2 days (28). Adults
can be infectious from the day before symptoms begin through
approximately 5 days after illness onset. Children can be in-
fectious for >10 days after the onset of symptoms, and young
children also can shed virus before their illness onset. Severely
immunocompromised persons can shed virus for weeks or
months (29–32).
Uncomplicated influenza illness is characterized by the
abrupt onset of constitutional and respiratory signs and symp-
toms (e.g., fever, myalgia, headache, malaise, nonproductive
cough, sore throat, and rhinitis) (33). Among children, otitis
media, nausea, and vomiting also are commonly reported with
influenza illness (34–36). Uncomplicated influenza illness
typically resolves after 3–7 days for the majority of persons,
although cough and malaise can persist for >2 weeks. How-
ever, among certain persons, influenza can exacerbate under-
lying medical conditions (e.g., pulmonary or cardiac disease),
lead to secondary bacterial pneumonia or primary influenza
viral pneumonia, or occur as part of a coinfection with other
viral or bacterial pathogens (37). Young children with influ-
enza virus infection can have initial symptoms mimicking
bacterial sepsis with high fevers (37,38), and febrile seizures
have been reported in up to 20% of children hospitalized
with influenza virus infection (35,39). Influenza virus infec-
tion also has been uncommonly associated with encephal-
opathy, transverse myelitis, myositis, myocarditis, pericarditis,
and Reye syndrome (35,37,40,41).
Respiratory illnesses caused by influenza viruses are diffi-
cult to distinguish from illnesses caused by other respiratory
pathogens on the basis of signs and symptoms alone (see Role
of Laboratory Diagnosis). Reported sensitivities and speci-
ficities of clinical definitions of influenza infection that in-
clude fever and cough in studies primarily among adults have
ranged from 63% to 78% and 55% to 71%, respectively, com-
pared with viral culture (42,43). Sensitivity and predictive
value of clinical definitions can vary, depending on the de-
gree of co-circulation of other respiratory pathogens and the
level of influenza activity (44). A study of older
nonhospitalized patients determined that the presence of fe-
ver, cough, and acute onset had a positive predictive value of
only 30% for influenza (45), whereas a study of hospitalized
older patients with chronic cardiopulmonary disease deter-
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mined that a combination of fever, cough, and illness of <7
days was 78% sensitive and 73% specific for influenza (46).
A study of vaccinated older persons with chronic lung disease
indicated that cough was not predictive of influenza virus
infection, although having a fever or feverishness was 68%
sensitive and 54% specific for influenza virus infection (47).
These results highlight the challenges of identifying influenza
illness in the absence of laboratory confirmation.
Hospitalizations and Deaths from Influenza
The risks for complications, hospitalizations, and deaths
from influenza are higher among persons aged >65 years,
young children, and persons of any age with certain underly-
ing health conditions (see Persons at Increased Risk for Com-
plications) than among healthy older children and younger
adults (1,6,8,48–56). Estimated rates of influenza-associated
hospitalizations have varied substantially by age group in stud-
ies conducted during different influenza epidemics (Table 1).
Among children aged <5 years, hospitalization rates have
ranged from approximately 500/100,000 children for those with
high-risk medical conditions to 100/100,000 children for those
without high-risk medical conditions (57–60). Hospitalization
rates among children aged <24 months are comparable to rates
reported among persons aged >65 years (59,60) (Table 1).
During seasonal influenza epidemics from 1979–80 through
2000–01, the estimated overall number of influenza-
associated hospitalizations in the United States ranged from
approximately 54,000 to 430,000/epidemic. An average of
approximately 226,000 influenza-related excess hospitaliza-
tions occurred per year, and 63% of all hospitalizations oc-
curred among persons aged >65 years (61). Since the 1968
influenza A (H3N2) virus pandemic, the number of influenza-
associated hospitalizations is generally greater during seasonal
influenza epidemics caused by type A (H3N2) viruses than
seasons in which other influenza virus types predominate (62).
Influenza-related deaths can result from pneumonia and
from exacerbations of cardiopulmonary conditions and other
chronic diseases. Deaths of adults aged >65 years account for
>90% of deaths attributed to pneumonia and influenza (1,54).
In one study, approximately 19,000 influenza-associated pul-
monary and circulatory deaths per influenza season occurred
during 1976–1990, compared with approximately 36,000
deaths during 1990–1999 (1). Estimated rates of influenza-
associated pulmonary and circulatory deaths/100,000 persons
were 0.4–0.6 among persons aged 0–49 years, 7.5 among
persons aged 50–64 years, and 98.3 among persons aged >65
years. In the United States, the number of influenza-
associated deaths has increased in part because the number of
older persons is increasing, particularly persons aged >85 years
(63). In addition, influenza seasons in which influenza A
(H3N2) viruses predominate are associated with higher mor-
tality (64); influenza A (H3N2) viruses predominated in 90%
of influenza seasons during 1990–1999, compared with 57%
of influenza seasons during 1976–1990 (1).
Deaths from influenza are uncommon among children both
with and without high-risk conditions, but do occur (65,66).
A study that modeled influenza-related deaths estimated that
an average of 92 deaths (0.4 deaths per 100,000) occurred
among children aged <5 years annually during the 1990s,
compared with 32,651 deaths (98.3 per 100,000) among
adults aged >65 years (1). Of 153 laboratory-confirmed
influenza-related pediatric deaths reported from 40 states dur-
ing the 2003–04 influenza season, 96 (63%) were among
children aged <5 years. Sixty-four (70%) of the 92 children
aged 2–17 years with influenza who died had no underlying
medical condition previously associated with an increased risk
for influenza-related complications (67).
Options for Controlling Influenza
In the United States, the primary option for reducing the
effect of influenza is through annual vaccination. Inactivated
(i.e., killed virus) influenza vaccines and LAIV are licensed
and available for use in the United States (see Recommenda-
tions for Using Inactivated and Live, Attenuated Influenza
Vaccines). Vaccination coverage can be increased by adminis-
tering vaccine to persons during hospitalizations or routine
health-care visits, as well as at pharmacies, grocery stores,
workplaces, or other locations in the community before the
influenza season, therefore making special visits to physicians’
offices or clinics unnecessary. Achieving increased vaccina-
tion rates among persons living in closed settings (e.g., nurs-
ing homes and other chronic-care facilities) and among staff
can reduce the risk for outbreaks (13), especially when vac-
cine and circulating strains are well-matched. Vaccination of
health-care workers and other persons in close contact with
persons at increased risk for severe influenza illness also can
reduce transmission of influenza and subsequent influenza-
related complications. Antiviral drugs used for chemoprophy-
laxis or treatment of influenza are adjuncts to vaccine (see
Recommendations for Using Antiviral Agents for Influenza)
but are not substitutes for annual vaccination.
Influenza Vaccine Composition
Both the inactivated and live, attenuated vaccines prepared
for the 2006–07 season will include A/New Caledonia/20/
1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and
B/Malaysia/2506/2004-like antigens (for the A/Wisconsin/
67/2005 [H3N2]-like antigen, manufacturers may use the
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antigenically equivalent A/Hiroshima/52/2005 virus, and for
the B/Malaysia/2506/2004-like antigen, manufacturers may
use the antigenically equivalent B/Ohio/1/2005 virus). These
viruses will be used because they are representative of influ-
enza viruses that are anticipated to circulate in the United
States during the 2006–07 influenza season and have favor-
able growth properties in eggs. Because circulating influenza
A (H1N2) viruses are reassortants of influenza A (H1N1)
and A (H3N2) viruses, antibodies directed against influenza
A (H1N1) and influenza (H3N2) vaccine strains should pro-
vide protection against the circulating influenza A (H1N2)
viruses. Influenza viruses for both TIV and LAIV are initially
grown in embryonated hens eggs, and, therefore, might con-
tain limited amounts of residual egg protein. Therefore, per-
sons with a history of severe hypersensitivity, such as anaphy-
laxis, to eggs should not receive influenza vaccine.
For the inactivated vaccines, the vaccine viruses are made
noninfectious (i.e., inactivated or killed) (68). Only subvirion
and purified surface antigen preparations of the inactivated
vaccine are available. Manufacturing processes vary by manu-
facturer. Manufacturers might use different compounds to
inactivate influenza viruses and add antibiotics to prevent
bacterial contamination. Package inserts should be consulted
for additional information.
TABLE 1. Estimated rates of influenza-associated hospitalization, by age group and risk group for selected studies* — United
States
Hospitalizations/ Hospitalizations/
100,000 persons 100,000 persons
with high-risk without high-risk
Study years Population Age group conditions conditions
1973–1993†§¶ Tennessee 0–11 mos 1,900 496–1,038**
Medicaid 1–2 yrs 800 186
3–4 yrs 320 86
5–14 yrs 92 41
1992–1997††§§ Two health 0–23 mos 144–187
maintenance 2–4 yrs 0–25
organizations 5–17 yrs 8–12
1968–1969 Health 15–44 yrs 56–110 23–25
1970–1971 maintenance 45–64 yrs 392–635 13–23
1972–1973¶¶*** organization >65 yrs 399–518 —
1969–1995***††† National Hospital <65 yrs — 20–42§§§¶¶¶
1969–1995***††† Discharge Data >65 yrs — 125–228¶¶¶
1979–2001****†††† National Hospital All ages — 88§§§§
Discharge Data
* Rates were estimated in years and populations with low vaccination levels. Hospitalization rates can be expected to decrease as vaccination levels
increase. Vaccination can be expected to reduce influenza-related hospitalizations by 30%–70% among older persons and likely by even higher percent-
ages among younger age groups when vaccine and circulating influenza virus strains are antigenically similar.
† Source: Neuzil KM, Mellen BG, Wright PF, Mitchel EF, Griffin MR. Effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in
children. N Engl J Med 2000;342:225–31.
§ Outcomes were for acute cardiac or pulmonary conditions.
¶ Source: Neuzil KM, Wright PF, Mitchel EF, Griffin MR. Burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr
2000;137:856–64.
** The low estimate is for infants aged 6–11 months, and the high estimate is for infants aged 0–5 months.
†† Source: Izurieta HA, Thompson WW, Kramarz P, et al. Influenza and the rates of hospitalization for respiratory disease among infants and young
children. N Engl J Med 2000;342:232–9.
§§ Outcomes were for acute pulmonary conditions. Influenza-attributable hospitalization rates for children at high risk were not included in this study.
¶¶ Source: Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798–811.
*** Outcomes were limited to hospitalizations in which either pneumonia or influenza was listed as the first condition on discharge records (Simonsen) or
included anywhere in the list of discharge diagnoses (Barker).
††† Source: Simonsen L, Fukuda K, Schonberger LB, Cox NJ. Impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181:831–7.
§§§ Persons at high risk and not at high risk for influenza-related complications are combined.
¶¶¶ The low estimate is the average during influenza A (H1N1) or influenza B-predominant seasons, and the high estimate is the average during influenza
A (H3N2)-predominant seasons.
**** Outcomes were for rate of primary respiratory and circulatory hospitalizations.
†††† Source: Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333–40.
§§§§ Rate for all ages of persons, both with and without high-risk conditions.
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Comparison of LAIV with Inactivated
Influenza Vaccine
Both inactivated influenza vaccine and LAIV are available.
Although both types of vaccines are effective, the vaccines
differ in several aspects (Table 2).
Major Similarities
Both LAIV and inactivated influenza vaccines contain
strains of influenza viruses that are antigenically equivalent to
the annually recommended strains: one influenza A (H3N2)
virus, one A (H1N1) virus, and one B virus. Each year, one
or more virus strains might be changed on the basis of global
surveillance for influenza viruses and the emergence and spread
of new strains. Viruses for both vaccines are grown in eggs.
Both vaccines are administered annually to provide optimal
protection against influenza virus infection (Table 2).
Major Differences
Inactivated influenza vaccine contains killed viruses, and
thus cannot produce signs or symptoms of influenza virus
infection. In contrast, LAIV contains live, attenuated viruses
and, therefore, has a potential to produce mild signs or symp-
toms related to influenza virus infection. LAIV is adminis-
tered intranasally by sprayer, whereas inactivated influenza
vaccine is administered intramuscularly by injection. LAIV is
more expensive than inactivated influenza vaccine, although
the price differential between inactivated vaccine and LAIV
has decreased for the 2006–07 season. LAIV is approved only
for use among healthy persons aged 5–49 years; inactivated
influenza vaccine is approved for use among persons aged >6
months, including those who are healthy and those with
chronic medical conditions (Table 2).
Efficacy and Effectiveness of Inactivated
Influenza Vaccine
The effectiveness of inactivated influenza vaccine depends
primarily on the age and immunocompetence of the vaccine
recipient, the degree of similarity between the viruses in the
vaccine and those in circulation, and the outcome being mea-
sured. Vaccine efficacy and effectiveness studies might have
various endpoints, including the prevention of medically at-
tended acute respiratory illness (MAARI), prevention of
culture-positive influenza virus illness, prevention of influ-
enza or pneumonia-associated hospitalizations or deaths,
seroconversion to vaccine serotypes, or prevention of
seroconversion to circulating influenza virus subtypes. High
TABLE 2. Live, attenuated influenza vaccine (LAIV) compared with inactivated influenza vaccine
Factor LAIV Inactivated influenza vaccine
Route of administration Intranasal spray Intramuscular injection
Type of vaccine Live virus Killed virus
No. of included virus strains 3 (2 influenza A, 3 (2 influenza A,
1 influenza B) 1 influenza B)
Vaccine virus strains updated Annually Annually
Frequency of administration Annually Annually
Approved age and risk groups* Healthy persons Persons aged >6 mos
aged 5–49 yrs
Interval between two doses recommended for children aged 6 mos– 6–10 wks 4 weeks
<9 yrs who are receiving influenza vaccine for the first time
Can be administered to family members or close contacts Yes Yes
of immunocompromised persons not requiring a protected environment
Can be administered to family members or close contacts Inactivated influenza Yes
of immunocompromised persons requiring a protected environment vaccine preferred
(e.g., hematopoietic stem cell transplant recipient)
Can be administered to family members or close contacts of persons Yes Yes
 at high risk but not severely immunocompromised
Can be simultaneously administered with other vaccines Yes† Yes§
If not simultaneously administered, can be administered Prudent to space Yes
within 4 wks of another live vaccine 4 wks apart
If not simultaneously administered, can be administered Yes Yes
within 4 wks of an inactivated vaccine
* Populations at high risk for complications of influenza infection include persons aged >65 years; residents of nursing homes and other chronic-care
facilities that house persons with chronic medical conditions; adults and children with chronic disorders of the pulmonary or cardiovascular systems;
adults and children with chronic metabolic diseases (including diabetes mellitus), renal dysfunction, hemoglobinopathies, or immunnosuppression;
children and adolescents receiving long-term aspirin therapy (at risk for Reye syndrome after wild-type influenza infection); pregnant women; and children
aged 6–59 months.
†No data are available regarding effect on safety or efficacy.
§ Inactivated influenza vaccine coadministration has been evaluated systematically only among adults with pneumococcal polysaccharide vaccine.
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postvaccination hemagglutination inhibition antibody titers
develop in the majority of vaccinated children and young
adults (69–71). These antibodies are protective against illness
caused by strains that are antigenically similar to those strains
of the same type or subtype included in the vaccine (70–73).
Children. Children aged >6 months usually acquire pro-
tective levels of anti-influenza antibody against specific influ-
enza virus strains after influenza vaccination (69,70,74–79),
although the antibody response among children at high risk
for influenza-related complications might be lower than
among healthy children (80,81). A 2-year randomized study
of children aged 6–24 months determined that 89% of chil-
dren seroconverted to all three vaccine strains during both
years (82). During year 1, among 411 children, vaccine effi-
cacy was 66% (95% confidence interval [CI] = 34%–82%)
against culture-confirmed influenza (attack rates: 5.5% and
15.9% among vaccine and placebo groups, respectively).
During year 2, among 375 children, vaccine efficacy was -7%
(CI = -247%–67%; attack rates: 3.6% and 3.3% among vac-
cine and placebo groups, respectively); the second year exhib-
ited lower attack rates overall and was considered a mild season.
In both years of this study, the vaccine strains were well-
matched to the circulating influenza virus strains.
A randomized study among children aged 1–15 years also
demonstrated that inactivated influenza vaccine was 77% and
91% effective against influenza respiratory illness during
H3N2 and H1N1 years, respectively (71). One study docu-
mented a vaccine efficacy of 56% against influenza illness
among healthy children aged 3–9 years (83), and another study
determined vaccine efficacy against influenza type B infec-
tion and influenza type A infection of 22%–54% and 60%–
78% among children with asthma aged 2–6 years and 7–14
years, respectively (84). Two studies have documented that
TIV vaccine decreases the incidence of influenza-associated
otitis media among young children by approximately 30%
(16,17), whereas a third study determined that vaccination
did not reduce the burden of acute otitis media (82).
Effectiveness of One Dose versus Two Doses of Influ-
enza Vaccine Among Previously Unvaccinated Children
Aged <9 Years. Vaccine effectiveness is lower among previ-
ously unvaccinated children aged <9 years if they have only
received 1 dose of influenza vaccine, compared with children
who have received 2 doses. A retrospective study among ap-
proximately 5,000 children aged 6–23 months conducted
during a year with a suboptimal vaccine match indicated vac-
cine effectiveness of 49% against medically attended, clini-
cally diagnosed pneumonia or influenza among children who
had received 2 doses of influenza vaccine. No effectiveness
was demonstrated among children who had received only 1
dose of influenza vaccine, illustrating the importance of ad-
ministering 2 doses of vaccine to previously unvaccinated
children aged <9 years (85). Similar results were observed in a
case-control study of children aged 6–59 months with
laboratory-confirmed influenza (86). A study assessing pro-
tective antibody responses after 1 and 2 doses of vaccine among
vaccine-naive children aged 5–8 years also demonstrated the
importance of compliance with the 2-dose recommendation
(87). When the vaccine antigens do not change from one sea-
son to the next, priming with a single dose of vaccine in the
spring, followed by a dose in the fall might result in similar
antibody responses to a 2-dose regimen in the fall (88,89).
Adults Aged <65 Years. When the vaccine and circulating
viruses are antigenically similar, influenza vaccine typically
prevents influenza illness among approximately 70%–90%
of healthy adults aged <65 years (9,12,90,91). Vaccination of
healthy adults also has resulted in decreased work absentee-
ism and decreased use of health-care resources, including use
of antibiotics, when the vaccine and circulating viruses are
well-matched (9–12,91,92). In a case-control study of adults
aged 50–64 years with laboratory-confirmed influenza dur-
ing the 2003–04 season when the vaccine and circulating vi-
ruses were not well-matched, vaccine effectiveness was
estimated to be 52% among healthy persons and 38% among
those with one or more high-risk conditions (93).
Adults Aged >65 Years. An important benefit of the influ-
enza vaccine is its ability to help prevent secondary complica-
tions and reduce the risk for influenza-related hospitalization
and death among adults aged >65 years with and without
high-risk medical conditions (e.g., heart disease and diabe-
tes) (13–15,18,94,95). Older persons and persons with cer-
tain chronic diseases might have lower postvaccination
antibody titers than healthy young adults and can remain sus-
ceptible to influenza virus infection and influenza-related
upper respiratory tract illness (96–98). A randomized trial
among noninstitutionalized persons aged >60 years reported
a vaccine efficacy of 58% against influenza respiratory illness
but indicated that efficacy might be lower among those aged
>70 years (99). However, among older persons not living in
nursing homes or similar chronic-care facilities, influenza
vaccine is 30%–70% effective in preventing hospitalization
for pneumonia and influenza (15,100). Among older persons
who reside in nursing homes, influenza vaccine is most effec-
tive in preventing severe illness, secondary complications, and
deaths. In this population, the vaccine can be 50%–60% ef-
fective in preventing influenza-related hospitalization or pneu-
monia and 80% effective in preventing influenza-related death,
although the effectiveness in preventing influenza illness of-
ten ranges from 30% to 40% (101–103).
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Efficacy and Effectiveness of LAIV
The immunogenicity of the approved LAIV has been as-
sessed in multiple studies (104–110), which included approxi-
mately 100 children aged 5–17 years and approximately 300
adults aged 18–49 years. LAIV virus strains replicate prima-
rily in nasopharyngeal epithelial cells. The protective mecha-
nisms induced by vaccination with LAIV are not completely
understood but appear to involve both serum and nasal secre-
tory antibodies. No single laboratory measurement closely
correlates with protective immunity induced by LAIV.
Healthy Children. A randomized, double-blind, placebo-
controlled trial among 1,602 healthy children initially aged
15–71 months assessed the efficacy of trivalent LAIV against
culture-confirmed influenza during two seasons (111,112).
This trial included subsets of 238 healthy children (163
vaccinees and 75 placebo recipients) aged 60–71 months who
received 2 doses and 74 children (54 vaccinees and 20 pla-
cebo recipients) aged 60–71 months who received a single
dose during season one, and a subset of 544 children (375
vaccinees and 169 placebo recipients) aged 60–84 months
during season two. Children who continued in the study re-
mained in the same study group. In season one, when vaccine
and circulating virus strains were well-matched, efficacy was
93% for participants who received 2 doses of LAIV. In season
two, when the A (H3N2) component was not well-matched
between vaccine and circulating virus strains, efficacy was 86%
overall. The vaccine was 92% efficacious in preventing culture-
confirmed influenza during the two-season study. Other re-
sults included a 27% reduction in febrile otitis media and a
28% reduction in otitis media with concomitant antibiotic
use. Receipt of LAIV also resulted in 21% fewer febrile ill-
nesses. A review of LAIV effectiveness in children aged 18
months–18 years found effectiveness against MAARI of 18%
but greater estimated efficacy levels: 92% against influenza A
(H1N1) and 66% against an influenza B drift variant (113).
Healthy Adults. A randomized, double-blind, placebo-
controlled trial among 4,561 healthy working adults aged 18–
64 years assessed multiple endpoints, including reductions in
self-reported respiratory tract illness without laboratory con-
firmation, absenteeism, health-care visits, and medication use
during peak and total influenza outbreak periods (114). The
study was conducted during the 1997–98 influenza season,
when the vaccine and circulating A (H3N2) strains were not
well-matched. During peak outbreak periods, no difference
in febrile illnesses between LAIV and placebo recipients was
observed. However, vaccination was associated with reduc-
tions in severe febrile illnesses of 19% and febrile upper respi-
ratory tract illnesses of 24%. Vaccination also was associated
with fewer days of illness, fewer days of work lost, fewer days
with health-care–provider visits, and reduced use of prescrip-
tion antibiotics and over-the-counter medications. Among a
subset of 3,637 healthy adults aged 18–49 years, LAIV re-
cipients (n = 2,411) had 26% fewer febrile upper-respiratory
illness episodes; 27% fewer lost work days as a result of fe-
brile upper respiratory illness; and 18%–37% fewer days of
health-care–provider visits caused by febrile illness, compared
with placebo recipients (n = 1,226). Days of antibiotic use
were reduced by 41%–45% in this age subset.
A randomized, double-blind, placebo-controlled challenge
study among 92 healthy adults (LAIV, n = 29; placebo, n =
31; inactivated influenza vaccine, n = 32) aged 18–41 years
assessed the efficacy of both LAIV and inactivated vaccine
(115). The overall efficacy of LAIV and inactivated influenza
vaccine in preventing laboratory-documented influenza from
all three influenza strains combined was 85% and 71%, re-
spectively, on the basis of experimental challenge by viruses
to which study participants were susceptible before vaccina-
tion. The difference in efficacy between the two vaccines was
not statistically significant.
Cost-Effectiveness of Influenza Vaccine
Influenza vaccination can reduce both health-care costs and
productivity losses associated with influenza illness. Studies
of influenza vaccination of persons aged >65 years conducted
in the United States have reported substantial reductions in
hospitalizations and deaths and overall societal costs savings
(15,100,104). Studies of adults aged <65 years have indicated
that vaccination can reduce both direct medical costs and in-
direct costs from work absenteeism (8,10–12,91,116). Re-
ductions of 13%–44% in health-care–provider visits,
18%–45% in lost workdays, 18%–28% in days working with
reduced effectiveness, and 25% in antibiotic use for influenza-
associated illnesses have been reported (10,12,117,118). One
cost-effectiveness analysis estimated a cost of approximately
$60–$4,000/illness averted among healthy persons aged 18–
64 years, depending on the cost of vaccination, the influenza
attack rate, and vaccine effectiveness against influenza-like ill-
ness (ILI) (91). Another cost-benefit economic study estimated
an average annual savings of $13.66/person vaccinated (119).
In the second study, 78% of all costs prevented were costs
from lost work productivity, whereas the first study did not
include productivity losses from influenza illness.
Economic studies specifically evaluating the cost-
effectiveness of vaccinating persons aged 50–64 years are not
available, and the number of studies that examine the eco-
nomics of routinely vaccinating children with TIV or LAIV
are limited (8,120–123). However, in a study of inactivated
vaccine that included all age groups, cost utility (i.e., cost per
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year of healthy life gained) improved with increasing age and
among those with chronic medical conditions (8). Among
persons aged >65 years, vaccination resulted in a net savings
per quality-adjusted life year (QALY) gained, whereas among
younger age groups, vaccination resulted in costs of $23–$256/
QALY.
In addition to estimating the economic cost associated with
influenza disease, studies have assessed the public’s percep-
tion of preventing influenza morbidity. Less than half of re-
spondents to a survey on public perception of the value of
preventing influenza morbidity reported that they would trade
any time from their own life to prevent a case of uncompli-
cated influenza in a hypothetical child (124). When asked
about their willingness to pay to prevent a hypothetical child
from having an uncomplicated case of influenza, the median
willingness-to-pay amount was $100 for a child aged 14 years
and $175 for a child aged 1 year (124).
Vaccination Coverage Levels
One of the national health objectives for 2010 is to achieve
an influenza vaccination coverage level of 90% for persons
aged >65 years (objective no. 14-29a) (125). Among persons
aged >65 years, influenza vaccination levels increased from
33% in 1989 (126) to 66% in 1999 (127), surpassing the
Healthy People 2000 objective of 60% (128). Vaccination cov-
erage in this group reached the highest levels recorded (68%)
during the 1999–00 influenza season. This estimate was made
using the percentage of adults reporting influenza vaccina-
tion during the previous 12 months in the National Health
Interview Survey (NHIS). The NHIS administered during
the first and second quarters of each calendar year was used as
a proxy measure of influenza vaccination coverage for the pre-
vious influenza season (127). Possible reasons for increases in
influenza vaccination levels among persons aged >65 years
include 1) greater acceptance of preventive medical services
by practitioners; 2) increased delivery and administration of
vaccine by health-care providers and sources other than phy-
sicians; 3) new information regarding influenza vaccine ef-
fectiveness, cost-effectiveness, and safety; and 4) initiation of
Medicare reimbursement for influenza vaccination in 1993
(8,14,15,101,102,129,130). Since 1997, influenza vaccina-
tion levels have increased more slowly, with an average an-
nual percentage increase of 4% from 1988–89 to 1996–97
versus 1% from 1996–97 to 1998–99. In 2000, a substantial
delay in influenza vaccine availability and distribution, fol-
lowed by a less severe delay in 2001 likely contributed to the
lack of progress. However, the slowing of the increase in vac-
cination levels began before 2000 and is not fully understood.
Estimated national influenza vaccine coverage in 2004
among persons aged >65 years and 50–64 years was 65% and
36%, respectively, based on 2004 NHIS data (Table 3). The
estimated vaccination coverage among adults with high-risk
conditions aged 18–49 years and 50–64 years was 26% and
46%, respectively, substantially lower than the Healthy People
2000 and 2010 objective of 60% (125,128). Continued an-
nual monitoring is needed to determine the effects of vaccine
supply delays and shortages, changes in influenza vaccination
recommendations and target groups for vaccination, reim-
bursement rates for vaccine and vaccine administration, and
other factors related to vaccination coverage among adults
and children. New strategies to improve coverage will be
needed to achieve the Healthy People 2010 objective (21,22).
Reducing racial and ethnic health disparities, including dis-
parities in vaccination coverage, is an overarching national
goal (125). Although estimated influenza vaccination cover-
age for the 1999–00 season reached the highest levels recorded
among older black, Hispanic, and white populations, vacci-
nation levels among blacks and Hispanics continue to lag
behind those among whites (127,131). Estimated vaccina-
tion coverage levels based on 2004 NHIS data among per-
sons aged >65 years were 67% among non-Hispanic whites,
45% among non-Hispanic blacks, and 55% among Hispan-
ics (CDC, unpublished data, 2006). Among Medicare ben-
eficiaries, unequal access to care might not be the only factor
in contributing toward disparity levels in influenza vaccina-
tion; other key factors include having patients that actively
seek vaccination and providers that recommend vaccination
(132,133).
In 1997 and 1998, vaccination coverage estimates among
nursing home residents were 64%–82% and 83%, respec-
tively (134,135). The Healthy People 2010 goal is to achieve
influenza vaccination of 90% among nursing home residents,
an increase from the Healthy People 2000 goal of 80%
(125,128).
Reported vaccination levels are low among children at in-
creased risk for influenza complications. One study conducted
among patients in health maintenance organizations (HMOs)
documented influenza vaccination percentages ranging from
9% to 10% among children with asthma (136). A 25% vac-
cination level was reported among children with severe to mod-
erate asthma who attended an allergy and immunology clinic
(137). However, a study conducted in a pediatric clinic dem-
onstrated an increase in the vaccination percentage of chil-
dren with asthma or reactive airways disease from 5% to 32%
after implementing a reminder/recall system (138). One study
documented 79% vaccination coverage among children at-
tending a cystic fibrosis treatment center (139). According to
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2004 National Immunization Survey data, during the second
year of the encouragement for vaccination of children aged
6–23 months, 18% received one or more influenza vaccina-
tions and 8.4% received 2 doses if they were previously un-
vaccinated (140). A rapid analysis of influenza vaccination
coverage levels among members of an HMO in Northern Cali-
fornia determined that in 2004–05, the first year of the rec-
ommendation for vaccination of children aged 6–23 months,
their coverage level reached 57% (141). Data from the Be-
havioral Risk Factor Surveillance System (BRFSS) collected
in February 2005 indicated a national estimate of 48% vacci-
nation coverage for 1 or more doses among children aged 6–
23 months and 35% coverage among children aged 2–17 years
who had one or more high-risk medical conditions during
the 2004–05 season (142). Increasing vaccination coverage
among persons who have high-risk conditions and are aged
<65 years, including children at high risk, is the highest pri-
ority for expanding influenza vaccine use. As has been ob-
served for older adults, a physician recommendation for
vaccination and the perception that getting a child vaccinated
“is a smart idea” were positively associated with likelihood of
vaccination of children aged 6–23 months (143).
Annual vaccination is recommended for health-care work-
ers. Nonetheless, NHIS 2004 survey data indicated a vacci-
nation coverage level of only 42% among health-care workers
(CDC, unpublished data, 2006). Vaccination of health-care
workers has been associated with reduced work absenteeism
(9) and fewer deaths among nursing home patients (144,145)
and is a high priority for reducing the effect of influenza in
health-care settings and for expanding influenza vaccine use
(146,147).
Limited information is available regarding use of influenza
vaccine among pregnant women. Among women aged 18–
44 years without diabetes responding to the 2001 BRFSS,
those who were pregnant were less likely to report influenza
vaccination during the previous 12 months (13.7%) than those
women who were not pregnant (16.8%); these differences were
statistically significant (148). Only 13% of pregnant women
reported vaccination according to 2004 NHIS data, exclud-
ing pregnant women who reported diabetes, heart disease,
TABLE 3. Influenza vaccination coverage levels among adult target* population groups — National Health Interview Survey
(NHIS), United States, 2004
Crude Weighted
Influenza vaccination level
Population group sample size sample size % (95% CI†)
All aged 18–49 yrs 18,039 130,493,300 17.9 (17.2–18.6)
All aged 50–64 yrs 6,933 47,757,000 35.9 (34.5–37.3)
All aged >65 yrs 5,922 34,019,100 64.6 (63.2–66.0)
Persons with high-risk conditions§
Aged 18–49 yrs 2,555 17,599,700 26.0 (23.9–28.1)
Aged 50–64 yrs 2,104 14,126,700 45.5 (43.0–48.0)
Aged 18–64 yrs 4,659 31,726,500 34.6 (33.0–36.4)
Persons without high-risk conditions§
Aged 18–49 yrs 15,442 112,574,500 16.6 (15.9–17.3)
Aged 50–64 yrs 4,807 33,498,900 32.1 (30.5–33.7)
Pregnant women¶ 263 1,967,400 12.9 (7.9–17.9)
Health-care workers** 2,031 14,376,900 41.9 (39.4–44.4)
Household contacts of persons at high risk,
including children aged <2 yrs††
Aged 18–49 yrs 2,365 19,212,100 15.4 (13.8–17.2)
Aged 50–64 yrs 480 4,202,500 33.2 (28.8–37.8)
* As recommended by the Advisory Committee on Immunization Practices.
† Confidence interval.
§ Persons categorized as being at high risk for influenza-related complications self-reported one or more of the following: 1) ever being told by a physician
they had diabetes, emphysema, coronary heart disease, angina, heart attack, or other heart condition; 2) having a diagnosis of cancer during the previous
12 months (excluding nonmelanoma skin cancer) or ever being told by a physician they have lymphoma, leukemia, or blood cancer during the previous 12
months; 3) being told by a physician they have chronic bronchitis or weak or failing kidneys; or 4) reporting an asthma episode or attack during the
preceding 12 months.
¶ Aged 18–44 years, pregnant at the time of the survey, and without high-risk conditions.
** Adults were classified as health-care workers if they were currently employed in a health-care occupation or in a health-care–industry setting, on the basis
of standard occupation and industry categories recoded in groups by CDC’s National Center for Health Statistics.
†† Interviewed adult in each household containing at least one of the following: a child aged <2 years, an adult aged >65 years, or any person aged 2–17
years at high risk (see previous § footnote). To obtain information on household composition and high-risk status of household members, the sampled
adult, child, and person files from NHIS were merged. Interviewed adults who were health-care workers or who had high-risk conditions were excluded.
Information could not be assessed regarding high-risk status of other adults aged 18–64 years in the household, thus, certain adults 18–64 years who live
with an adult aged 18–64 years at high risk were not included in the analysis.
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lung disease, and other selected high-risk conditions (CDC,
unpublished data, 2006) (Table 3). These data indicate low
compliance with the ACIP recommendations for pregnant
women. In a study of influenza vaccine acceptance by preg-
nant women, 71% who were offered the vaccine chose to be
vaccinated (149). However, a 1999 survey of obstetricians
and gynecologists determined that only 39% administered
influenza vaccine to obstetric patients, although 86% agreed
that pregnant women’s risk for influenza-related morbidity
and mortality increases during the last two trimesters (150).
Data indicate that self-report of influenza vaccination among
adults, compared with extraction from the medical record, is
both a sensitive and specific source of information (151).
Patient self-reports should be accepted as evidence of influ-
enza vaccination in clinical practice (151). However, infor-
mation on the validity of parents’ reports of pediatric influenza




The inactivated influenza vaccine and LAIV can be used to
reduce the risk for influenza virus infection and its complica-
tions. TIV is Food and Drug Administration (FDA)-approved
for persons aged >6 months, including those with high-risk
conditions, whereas LAIV is approved only for use among
healthy persons aged 5–49 years (see Inactivated Influenza
Vaccine Recommendations; and Live, Attenuated Influenza
Vaccine Recommendations).
Target Groups for Vaccination
Annual influenza vaccination is recommended for the
following groups:
Persons at Increased Risk for Complications
Vaccination with inactivated influenza vaccine is recom-
mended for the following persons who are at increased risk
for severe complications from influenza:
• children aged 6–23 months;
• children and adolescents (aged 6 months–18 years) who
are receiving long-term aspirin therapy and, therefore,
might be at risk for experiencing Reye syndrome after
influenza virus infection;
• women who will be pregnant during the influenza season;
• adults and children who have chronic disorders of the
pulmonary or cardiovascular systems, including asthma
(hypertension is not considered a high-risk condition);
• adults and children who have required regular medical
follow-up or hospitalization during the preceding year
because of chronic metabolic diseases (including diabe-
tes mellitus), renal dysfunction, hemoglobinopathies, or
immunodeficiency (including immunodeficiency caused
by medications or by human immunodeficiency virus
[HIV]);
• adults and children who have any condition (e.g., cogni-
tive dysfunction, spinal cord injuries, seizure disorders,
or other neuromuscular disorders) that can compromise
respiratory function or the handling of respiratory secre-
tions or that can increase the risk for aspiration;
• residents of nursing homes and other chronic-care facili-
ties that house persons of any age who have chronic medi-
cal conditions; and
• persons aged >65 years.
Vaccination with inactivated influenza vaccine also is rec-
ommended for the following persons because of an increased
risk for influenza-associated clinic, emergency department,
or hospital visits, particularly if they have a high-risk medical
condition:
• children aged 24–59 months and
• persons aged 50–64 years.
Persons Who Live With or Care for Persons
at High Risk for Influenza-Related
Complications
In addition, to prevent transmission to persons identified
above, vaccination with TIV or LAIV is recommended for
the following persons, unless contraindicated:
• healthy household contacts and caregivers of children aged
0–59 months and persons at high risk for severe compli-
cations from influenza and
• health-care workers.
In 2006, approximately 218.1 million persons in the United
States will be included in one or more of these target groups,
including 6.0 million children aged 6–23 months, 10.6 mil-
lion healthy children aged 24–59 months, 44.0 million per-
sons aged 2–64 years with one or more conditions associated
with an increased risk for influenza-related complications, 4.0
million pregnant women, 33.0 million healthy persons aged
50–64 years, approximately 2 million nursing home resi-
dents, 37.2 million persons aged >65 years, 94.8 million
healthy household contacts, and 7.0 million health-care work-
ers aged <65 years (CDC, unpublished data, 2006).
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Additional Information Regarding
Vaccination of Specific Populations
Healthy Young Children Aged 6–59 Months
Because children aged 6–23 months are at substantially in-
creased risk for influenza-related hospitalizations and because
children aged 24–59 months are at increased risk for influ-
enza-related clinic and emergency department visits (152),
ACIP recommends vaccination of children aged 6–59 months.
The current LAIV and inactivated influenza vaccines are not
approved by FDA for use among children aged <6 months,
the pediatric group at greatest risk for influenza-related com-
plications (58,153,154). Vaccination of their household con-
tacts and out-of-home caregivers also is recommended because
it might decrease the probability of influenza virus infection
among these children.
Studies indicate that rates of hospitalization are higher among
young children than older children when influenza viruses are
in circulation (57,59–61,62,155–157). The increased rates of
hospitalization are comparable with rates for other groups con-
sidered at high risk for influenza-related complications. How-
ever, the interpretation of these findings has been confounded
by cocirculation of respiratory syncytial virus that causes seri-
ous respiratory viral illness among children and that frequently
circulates during the same time as influenza viruses (158–160).
One study assessed rates of influenza-associated hospitaliza-
tions among the entire U.S. population during 1979–2001
and calculated an average rate of approximately 108 hospital-
izations per 100,000 person-years in children aged <5 years
(48). Two studies have attempted to separate the impact of
respiratory syncytial viruses and influenza viruses on rates of
hospitalization among children who do not have high-risk con-
ditions (58,59). Both studies indicated that otherwise healthy
children aged <2 years and possibly children aged 2–4 years are
at increased risk for influenza-related hospitalization compared
with older healthy children (Table 1). Among the Tennessee
Medicaid population during 1973–1993, healthy children aged
6 months–2 years had rates of influenza-associated hospital-
ization comparable with or higher than rates among children
aged 3–14 years with high-risk conditions (58,60). Another
Tennessee study indicated a hospitalization rate per year of 3–
4/1,000 healthy children aged <2 years for laboratory-con-
firmed influenza (36).
The ability of providers to implement the recommenda-
tion to vaccinate all children aged 24–59 months during the
2006–07 season, the first year the recommendation will be in
place, might vary depending upon vaccine supply (See Influ-




Influenza-associated excess deaths among pregnant women
were documented during the pandemics of 1918–19 and
1957–58 (51,161–163). Case reports and limited studies also
indicate that pregnancy can increase the risk for serious medical
complications of influenza (164–169). One study of influ-
enza vaccination of approximately 2,000 pregnant women
demonstrated no adverse fetal effects associated with inacti-
vated influenza vaccine (170); similar results were observed
in a study of 252 pregnant women who received inactivated
influenza vaccine within 6 months of delivery (171). No such
data exist on the safety of LAIV when administered during
pregnancy.
Breastfeeding Mothers
TIV is safe for mothers who are breastfeeding and their
infants. Because excretion of LAIV in human milk is unknown
and because of the possibility of shedding vaccine virus given
the close proximity of a nursing mother and her infant, cau-
tion should be exercised if LAIV is administered to nursing
mothers. Breastfeeding does not adversely affect the immune
response and is not a contraindication for vaccination.
Persons Aged 50–64 Years
Vaccination is recommended for persons aged 50–64 years
because this group has an increased prevalence of persons with
high-risk conditions. In 2002, approximately 43.6 million
persons in the United States were aged 50–64 years, of whom
13.5 million (34%) had one or more high-risk medical con-
ditions (172). Influenza vaccine has been recommended for
this entire age group to increase the low vaccination levels
among persons in this age group with high-risk conditions
(see Persons at Increased Risk for Complications). Age-based
strategies are more successful in increasing vaccine coverage
than patient-selection strategies based on medical conditions.
Persons aged 50–64 years without high-risk conditions also
receive benefit from vaccination in the form of decreased rates
of influenza illness, decreased work absenteeism, and decreased
need for medical visits and medication, including antibiotics
(9–12). Furthermore, 50 years is an age when other preven-
tive services begin and when routine assessment of vaccina-
tion and other preventive services has been recommended
(173,174).
Health-Care Workers and Other Persons Who
Can Transmit Influenza to Those at High Risk
Persons who are clinically or asymptomatically infected can
transmit influenza virus to persons at high risk for complica-
tions from influenza. Decreasing transmission of influenza
from caregivers and household contacts to persons at high
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risk might reduce influenza-related deaths among persons at
high risk. In two studies, vaccination of health-care workers
was associated with decreased deaths among nursing home
patients (144,145), and hospital-based influenza outbreaks
frequently occur where unvaccinated health-care workers are
employed. Administration of LAIV has been demonstrated
to reduce MAARI in contacts of vaccine recipients (175,176)
and to reduce ILI-related economic and medical consequences
(such as work days lost and number of health-care provider
visits). In addition to health-care workers, additional groups
that can transmit influenza to persons at high risk and that
should be vaccinated include the following:
• employees of assisted living and other residences for per-
sons in groups at high risk,
• persons who provide home care to persons in groups at
high risk, and
• household contacts (including children) of persons in
groups at high risk.
In addition, because children aged 0–23 months are at in-
creased risk for influenza-related hospitalization (58–60), vac-
cination is recommended for their household contacts and
out-of-home caregivers, particularly for contacts of children
aged 0–5 months, because influenza vaccines have not been
approved by FDA for use among children aged <6 months
(see Healthy Young Children Aged 6–59 Months).
Healthy persons aged 5–49 years in these groups who are
not contacts of severely immunocompromised persons (see
Live, Attenuated Influenza Vaccine Recommendations) can
receive either LAIV or inactivated influenza vaccine. All other
persons in this group should receive inactivated influenza
vaccine.
All health-care workers should be vaccinated against influ-
enza annually (147,177,178). Facilities that employ health-
care workers are strongly encouraged to provide vaccine to
workers by using approaches that maximize vaccination lev-
els. An improvement in vaccination coverage levels might help
to protect health-care workers, their patients, and communi-
ties; improve prevention of influenza-associated disease and
patient safety; and reduce disease burden. Influenza vaccina-
tion levels among health-care workers should be regularly mea-
sured and reported. Although vaccination levels for health-care
workers are typically <40%, with moderate effort, organized
campaigns can attain higher levels of vaccination among this
population (146,179). In 2005, seven states had legislation
requiring annual influenza vaccination of health-care work-
ers or the signing of an informed declination (147), and 15
states had regulations regarding vaccination of health-care
workers in long-term–care facilities (180). Physicians, nurses,
and other workers in both hospital and outpatient-care set-
tings, including medical emergency-response workers (e.g.,
paramedics and emergency medical technicians), should be
vaccinated, as should employees of nursing home and chronic-
care facilities who have contact with patients or residents.
Persons Infected with HIV
Limited information is available regarding the frequency
and severity of influenza illness or the benefits of influenza
vaccination among persons with HIV infection (181,182).
However, a retrospective study of young and middle-aged
women enrolled in Tennessee’s Medicaid program determined
that the risk for cardiopulmonary hospitalizations among
women with HIV infection was higher during influenza sea-
sons than during the peri-influenza periods. The risk for hos-
pitalization was higher for HIV-infected women than for
women with other well-recognized high-risk conditions, in-
cluding chronic heart and lung diseases (183). Another study
estimated that the risk for influenza-related death was 9.4–
14.6/10,000 persons with acquired immunodeficiency syn-
drome (AIDS), compared with 0.09–0.10/10,000 among all
persons aged 25–54 years and 6.4–7.0/10,000 among per-
sons aged >65 years (184). Other reports indicate that influ-
enza symptoms might be prolonged and the risk for
complications from influenza increased for certain HIV-
infected persons (185–187).
Vaccination has been demonstrated to produce substantial
antibody titers against influenza among vaccinated HIV-
infected persons who have minimal AIDS-related symptoms
and high CD4+ T-lymphocyte cell counts (188–191). A lim-
ited, randomized, placebo-controlled trial determined that
inactivated influenza vaccine was highly effective in prevent-
ing symptomatic, laboratory-confirmed influenza virus infec-
tion among HIV-infected persons with a mean of 400 CD4+
T-lymphocyte cells/mm3; a limited number of persons with
CD4+ T-lymphocyte cell counts of <200 were included in
that study (192). A nonrandomized study among HIV-
infected persons determined that influenza vaccination was
most effective among persons with >100 CD4+ cells and
among those with <30,000 viral copies of HIV type-1/mL
(187). Among persons who have advanced HIV disease and
low CD4+ T-lymphocyte cell counts, inactivated influenza
vaccine might not induce protective antibody titers (190,191);
a second dose of vaccine does not improve the immune re-
sponse in these persons (191,192).
One case study determined that HIV RNA (ribonucleic
acid) levels increased transiently in one HIV-infected person
after influenza virus infection (193). Studies have demon-
strated a transient (i.e., 2–4 week) increase in replication of
HIV-1 in the plasma or peripheral blood mononuclear cells
of HIV-infected persons after vaccine administration
(190,194). Other studies using similar laboratory techniques
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have not documented a substantial increase in the replication
of HIV (195–198). Deterioration of CD4+ T-lymphocyte cell
counts or progression of HIV disease has not been demon-
strated among HIV-infected persons after influenza vaccina-
tion compared with unvaccinated persons (191,199). Limited
information is available concerning the effect of antiretroviral
therapy on increases in HIV RNA levels after either natural
influenza virus infection or influenza vaccination (181,200).
Because influenza can result in serious illness and because
vaccination with inactivated influenza vaccine might result
in the production of protective antibody titers, vaccination
might benefit HIV-infected persons, including HIV-infected
pregnant women. Therefore, influenza vaccination is
recommended.
Travelers
The risk for exposure to influenza during travel depends on
the time of year and destination. In the tropics, influenza can
occur throughout the year. In the temperate regions of the
Southern Hemisphere, the majority of influenza activity
occurs during April–September. In temperate climate zones
of the Northern and Southern Hemispheres, travelers also can
be exposed to influenza during the summer, especially when
traveling as part of large organized tourist groups (e.g., on
cruise ships) that include persons from areas of the world where
influenza viruses are circulating (201,202). Persons at high
risk for complications of influenza and who were not vacci-
nated with influenza vaccine during the preceding fall or winter
should consider receiving influenza vaccine before travel if
they plan to
• travel to the tropics,
• travel with organized tourist groups at any time of year, or
• travel to the Southern Hemisphere during April–
September.
No information is available regarding the benefits of revac-
cinating persons before summer travel who were already vac-
cinated during the preceding fall. Persons at high risk who
received the previous season’s vaccine before travel should be
revaccinated with the current vaccine the following fall or
winter. Persons aged >50 years and persons at high risk should
consult with their health-care provider before embarking on
travel during the summer to discuss the symptoms and risks
for influenza and other travel-related diseases.
General Population
In addition to the groups for which annual influenza vacci-
nation is recommended, vaccination providers should admin-
ister influenza vaccine to any person who wishes to reduce
the likelihood of becoming ill with influenza or transmitting
influenza to others should they become infected (the vaccine
can be administered to children aged >6 months), depending
on vaccine availability (see Influenza Vaccine Supply and Tim-
ing of Annual Influenza Vaccination). A strategy of universal
influenza vaccination is being assessed by ACIP.
Persons who provide essential community services should be
considered for vaccination to minimize disruption of essential
activities during influenza outbreaks. Students or other per-
sons in institutional settings (e.g., those who reside in dormi-
tories) should be encouraged to receive vaccine to minimize




Dosage recommendations vary according to age group
(Table 4). Among previously unvaccinated children aged
6 months–<9 years, 2 doses of inactivated vaccine adminis-
tered >1 month apart are recommended for eliciting satisfac-
tory antibody responses (85–88). If possible, the second dose
should be administered before the onset of influenza season.
If a child aged 6 months–<9 years receiving influenza vaccine
for the first time does not receive a second dose of vaccine
within the same season, only 1 dose of vaccine should be ad-
ministered the following season. Two doses are not required
at that time. ACIP does not recommend that a child receiv-
ing influenza vaccine for the first time be administered the
first dose of vaccine in the spring as a priming dose for the
following season (86,88).
Among adults, studies have indicated limited or no improve-
ment in antibody response when a second dose is adminis-
tered during the same season (204–206). Even when the
current influenza vaccine contains one or more antigens ad-
ministered in previous years, annual vaccination with the vac-
cine is necessary because immunity declines during the year
after vaccination (207,208). Vaccine prepared for a previous
influenza season should not be administered to provide pro-
tection for the current season (see Persons Who Should Not
Be Vaccinated with Inactivated Influenza Vaccine).
TIV Route
The intramuscular route is recommended for inactivated
influenza vaccine. Adults and older children should be vacci-
nated in the deltoid muscle. A needle length >1 inch should
be considered for these age groups because needles <1 inch
might be of insufficient length to penetrate muscle tissue in
certain adults and older children (209).
Infants and young children should be vaccinated in the
anterolateral aspect of the thigh (210). ACIP recommends a
needle length of 7/8–1 inch for children aged <12 months for
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intramuscular vaccination into the anterolateral thigh. When
injecting into the deltoid muscle among children with ad-
equate deltoid muscle mass, a needle length of 7/8–1.25 inches
is recommended (210).
TIV Side Effects and Adverse Reactions
When educating patients regarding potential side effects,
clinicians should emphasize that 1) inactivated influenza vac-
cine contains noninfectious killed viruses and cannot cause
influenza, and 2) coincidental respiratory disease unrelated
to influenza vaccination can occur after vaccination.
TIV Local Reactions
In placebo-controlled studies among adults, the most fre-
quent side effect of vaccination is soreness at the vaccination
site (affecting 10%–64% of patients) that lasts <2 days
(12,211–213). These local reactions typically are mild and
rarely interfere with the person’s ability to conduct usual daily
activities. One blinded, randomized, cross-over study among
1,952 adults and children with asthma demonstrated that only
body aches were reported more frequently after inactivated
influenza vaccine (25.1%) than placebo-injection (20.8%)
(214). One study reported 20%–28% of children with asthma
aged 9 months–18 years experienced local pain and swelling
(81), and another study reported 23% of children aged 6
months–4 years with chronic heart or lung disease had local
reactions (76). A different study reported no difference in
local reactions among 53 children aged 6 months–6 years with
high-risk medical conditions or among 305 healthy children
aged 3–12 years in a placebo-controlled trial of inactivated
influenza vaccine (77). In a study of 12 children aged 5–32
months, no substantial local or systemic reactions were noted
(215). The interpretation of these findings should be made
with caution given the small number of children studied.
TIV Systemic Reactions
Fever, malaise, myalgia, and other systemic symptoms can
occur after vaccination with inactivated vaccine and most of-
ten affect persons who have had no previous exposure to the
influenza virus antigens in the vaccine (e.g., young children)
(216,217). These reactions begin 6–12 hours after vaccina-
tion and can persist for 1–2 days. Placebo-controlled trials
demonstrate that among older persons and healthy young
adults, administration of split-virus influenza vaccine is not
associated with higher rates of systemic symptoms (e.g., fever,
malaise, myalgia, and headache) when compared with pla-
cebo injections (12,211–213).
In a randomized cross-over study among both children and
adults with asthma, no increase in asthma exacerbations was
reported for either age group (214). An analysis of 215,600
TABLE 4. Approved influenza vaccines for different age groups — United States, 2006–07 season
Thimerosal
mercury content
Dose/ (mcg Hg/0.5-mL No. of
Vaccine* Trade name Manufacturer Presentation dose) Age group doses Route
Inactivated
TIV Fluzone® sanofi pasteur 0.25-mL 0 6–35 mos 1 or 2† Intramuscular§
prefilled syringe
0.5-mL 0 >36 mos 1 or 2† Intramuscular§
prefilled syringe
0.5-mL vial 0 >36 mos 1 or 2† Intramuscular§
5.0-mL 25 >6 mos 1 or 2† Intramuscular§
multi-dose vial
TIV Fluvirin™ Novartis Vaccine 0.5-mL <1.0 >4 yrs 1 or 2† Intramuscular§
(formerly Chiron prefilled syringe
Corporation) 5.0-mL 24.5 >4 yrs 1 or 2† Intramuscular§
multi-dose vial
TIV FLUARIX™ GlaxoSmithKline 0.5-mL <1.25 >18 yrs 1 Intramuscular§
prefilled syringe
Live, attenuated
LAIV FluMist™ MedImmune 0.5-mL sprayer 0 5–49 yrs 1 or 2¶ Intranasal**
* A 0.5-mL dose contains 15 mcg each of A/New Caledonia/20/1999 (H1N1)-like, A/Wisconsin/67/2005 (H3N2)-like, and B/Malaysia/2506/2004-like anti-
gens. For the A/Wisconsin/67/2005 (H3N2)-like antigen, manufacturers may use the antigenically equivalent A/Hiroshima/52/2005 virus, and for the
B/Malaysia/2506/2004-like antigen, manufacturers may use the antigenically equivalent B/Ohio/1/2005 virus.
† Two doses administered at least 1 month apart are recommended for children aged 6 months–<9 years who are receiving influenza vaccine for the first
time.
§ For adults and older children, the recommended site of vaccination is the deltoid muscle. The preferred site for infants and young children is the anterolat-
eral aspect of the thigh.
¶ Two doses administered at least 6 weeks apart are recommended for children aged 5–<9 years who are receiving influenza vaccine for the first time.
** One dose equals 0.5 mL, divided equally between each nostril.
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children aged <18 years and 8,476 children aged 6–23 months
enrolled in one of five HMOs reported no increase in bio-
logically plausible medically attended events during the 2
weeks after inactivated influenza vaccination, compared with
control periods 3–4 weeks before and after vaccination (218).
In a study of 791 healthy children (71), postvaccination fever
was noted among 11.5% of children aged 1–5 years, among
4.6% of children aged 6–10 years, and among 5.1% of chil-
dren aged 11–15 years. Among children with high-risk medi-
cal conditions, one study of 52 children aged 6 months–4
years indicated that 27% had fever and 25% had irritability
and insomnia (76); another study among 33 children aged
6–18 months indicated that one child had irritability and one
had a fever and seizure after vaccination (219). No placebo
comparison group was used in these studies.
A published review of the Vaccine Adverse Event Report-
ing System (VAERS) reports of TIV in children aged 6–23
months documented that the most frequently reported ad-
verse events were fever, rash, injection-site reactions, and sei-
zures. The majority of the small total number of reported
seizures appeared to be febrile (220). Because of the limita-
tions of passive reporting systems, determining causality for
specific types of adverse events, with the exception of injection-
site reactions, is usually not possible using VAERS data alone.
A population-based study of TIV safety in children aged 6–
23 months who were vaccinated during 1993–1999 indicated
no vaccine-associated adverse events that had a plausible
relationship to vaccination (221).
Health-care professionals should promptly report to VAERS
all clinically significant adverse events after influenza vacci-
nation, even if the health-care professional is not certain that
the vaccine caused the event. The Institute of Medicine has
specifically recommended reporting of potential neurologic
complications (e.g., demyelinating disorders such as Guillain-
Barré syndrome [GBS]), although no evidence exists of a causal
relation between influenza vaccine and neurologic disorders
in children.
Immediate, presumably allergic, reactions (e.g., hives, an-
gioedema, allergic asthma, and systemic anaphylaxis) rarely
occur after influenza vaccination (222). These reactions prob-
ably result from hypersensitivity to certain vaccine compo-
nents; the majority of reactions probably are caused by residual
egg protein. Although current influenza vaccines contain only
a limited quantity of egg protein, this protein can induce
immediate hypersensitivity reactions among persons who have
severe egg allergy. Persons who have had hives or swelling of
the lips or tongue or who have experienced acute respiratory
distress or collapse after eating eggs should consult a physi-
cian for appropriate evaluation to help determine if vaccine
should be administered. Persons who have documented im-
munoglobulin E (IgE)-mediated hypersensitivity to eggs, in-
cluding those who have had occupational asthma or other
allergic responses to egg protein, might also be at increased
risk for allergic reactions to influenza vaccine, and consulta-
tion with a physician should be considered (223–225). Per-
sons with a history of severe hypersensitivity (e.g., anaphylaxis)
to eggs should not receive influenza vaccine.
Hypersensitivity reactions to any vaccine component can
occur theoretically. Although exposure to vaccines contain-
ing thimerosal can lead to induction of hypersensitivity, the
majority of patients do not have reactions to thimerosal when
it is administered as a component of vaccines, even when patch
or intradermal tests for thimerosal indicate hypersensitivity
(226,227). When reported, hypersensitivity to thimerosal
usually has consisted of local, delayed hypersensitivity
reactions (226).
GBS and TIV
The 1976 swine influenza vaccine was associated with an
increased frequency of GBS (228,229). Among persons who
received the swine influenza vaccine in 1976, the rate of GBS
was <10 cases/1 million persons vaccinated. The risk for in-
fluenza vaccine-associated GBS was higher among persons
aged >25 years than persons aged <25 years (228). Evidence
for a causal relation of GBS with subsequent vaccines pre-
pared from other influenza viruses is unclear. Obtaining strong
epidemiologic evidence for a possible limited increase in risk
is difficult for such a rare condition as GBS, which has an
estimated annual incidence of 10–20 cases/1 million adults
(230).
 Investigations to date have not documented a substantial
increase in GBS associated with influenza vaccines (other than
the swine influenza vaccine in 1976), and suggest that, if in-
fluenza vaccine does pose a risk, it is probably slightly more
than one additional case/1 million persons vaccinated. Dur-
ing three of four influenza seasons studied during 1977–1991,
the overall relative risk estimates for GBS after influenza vac-
cination were slightly elevated, but they were not statistically
significant in any of these studies (231–233). However, in a
study of the 1992–93 and 1993–94 influenza seasons, the
overall relative risk for GBS was 1.7 (CI = 1.0–2.8; p = 0.04)
during the 6 weeks after vaccination, representing approxi-
mately 1 additional case of GBS/1 million persons vaccinated;
the combined number of GBS cases peaked 2 weeks after vac-
cination (234). VAERS has documented decreased reporting of
postinfluenza vaccine GBS across age groups, despite overall
increased reporting of other, non-GBS conditions occurring after
influenza vaccination (235). Cases of GBS after influenza in-
fection have been reported, but no other epidemiologic studies
have documented such an association (236,237). Substantial
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evidence exists that several infectious illnesses, most notably
Campylobacter jejuni and upper respiratory tract infections are
associated with GBS (230,238–240).
Even if GBS were a true side effect of vaccination in the
years other than 1976, the estimated risk for GBS of approxi-
mately 1 additional case/1 million persons vaccinated is sub-
stantially less than the risk for severe influenza, which can be
prevented by vaccination among all age groups, especially
persons aged >65 years and those who have medical indica-
tions for influenza vaccination (Table 1) (see Hospitalizations
and Deaths from Influenza). The potential benefits of influ-
enza vaccination in preventing serious illness, hospitalization,
and death substantially outweigh the possible risks for expe-
riencing vaccine-associated GBS. The average case fatality ratio
for GBS is 6% and increases with age (230,241). No evi-
dence indicates that the case fatality ratio for GBS differs
among vaccinated persons and those not vaccinated.
The incidence of GBS among the general population is low,
but persons with a history of GBS have a substantially greater
likelihood of subsequently experiencing GBS than persons
without such a history (231,242). Thus, the likelihood of
coincidentally experiencing GBS after influenza vaccination
is expected to be greater among persons with a history of GBS
than among persons with no history of this syndrome.
Whether influenza vaccination specifically might increase the
risk for recurrence of GBS is unknown. However, avoiding
vaccinating persons who are not at high risk for severe influ-
enza complications and who are known to have experienced
GBS within 6 weeks after a previous influenza vaccination is
prudent. As an alternative, physicians might consider using
influenza antiviral chemoprophylaxis for these persons. Al-
though data are limited, for the majority of persons who have
a history of GBS and who are at high risk for severe compli-
cations from influenza, the established benefits of influenza
vaccination justify yearly vaccination.
Thimerosal and Inactivated Influenza Vaccine
Thimerosal, a mercury-containing compound, has been
used as a preservative in vaccines since the 1930s and is used
in multidose vials of inactivated influenza vaccine to reduce
the likelihood of bacterial contamination (243). Many of the
single-dose syringes and vials of TIV are thimerosal-free or
contain only trace amounts of thimerosal (Table 4). No sci-
entific evidence indicates that thimerosal in vaccines, includ-
ing influenza vaccines, leads to serious adverse events in vaccine
recipients (244). However, in 1999, the U.S. Public Health
Service and other organizations recommended that efforts be
made to eliminate or reduce the thimerosal content in vac-
cines to decrease total mercury exposure, chiefly among in-
fants (243–245). Since mid-2001, vaccines routinely
recommended for infants in the United States have been manu-
factured either without or with only trace amounts of thime-
rosal, resulting in a substantial reduction in the total mercury
exposure from vaccines for children (210). Vaccines contain-
ing trace amounts of thimerosal have <1 mcg mercury/dose.
The risks for severe illness from influenza virus infection
are elevated among both young children and pregnant women,
and persons in both groups benefit from vaccination. In con-
trast, no scientifically conclusive evidence exists of harm from
exposure to thimerosal preservative-containing vaccine. In fact,
evidence is accumulating that supports the absence of any
harm resulting from exposure to such vaccines (243,246–248).
Therefore, the benefits of influenza vaccination outweigh the
theoretical risk, if any, from thimerosal exposure through vac-
cination. Nonetheless, certain persons remain concerned re-
garding exposure to thimerosal. As of February 2006, six states
had enacted legislation banning the administration of vac-
cines containing mercury; the provisions defining mercury
content vary. These laws might present a barrier to vaccina-
tion until sufficient numbers of doses of influenza vaccines
without thimerosal as a preservative or in trace amounts are
available.
The U.S. vaccine supply for infants and pregnant women
is in a period of transition; the availability of thimerosal-
reduced or thimerosal-free vaccine intended for these groups
is being expanded by manufacturers as a feasible means of
reducing an infant’s total exposure to mercury, because other
environmental sources of exposure are more difficult or im-
possible to eliminate. Reductions in thimerosal in other vac-
cines have been achieved already and have resulted in
substantially lowered cumulative exposure to thimerosal
from vaccination among infants and children. For all of those
reasons, persons for whom inactivated influenza vaccine is
recommended may receive vaccine with or without thimerosal,
depending on availability.
Persons Who Should Not Be Vaccinated
with Inactivated Influenza Vaccine
Inactivated influenza vaccine should not be administered
to persons known to have anaphylactic hypersensitivity to eggs
or to other components of the influenza vaccine without first
consulting a physician (see Side Effects and Adverse Reac-
tions). Chemoprophylactic use of antiviral agents is an op-
tion for preventing influenza among such persons. However,
persons who have a history of anaphylactic hypersensitivity
to vaccine components but who also are at high risk for com-
plications from influenza can benefit from vaccine after ap-
propriate allergy evaluation and desensitization. Information
regarding vaccine components is located in package inserts
from each manufacturer. Persons with moderate-to-severe
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acute febrile illness usually should not be vaccinated until their
symptoms have abated. However, minor illnesses with or with-
out fever do not contraindicate use of influenza vaccine, par-
ticularly among children with mild upper-respiratory tract
infection or allergic rhinitis.
TIV and Use of Influenza Antiviral Medications
As TIV contains only influenza virus subunits and no live
virus, no contraindication exists to the coadministration of
TIV and influenza antivirals (see sections on Chemoprophy-
laxis; and Control of Influenza Outbreaks in Institutions).
Live, Attenuated Influenza Vaccine
Recommendations
Using LAIV
LAIV is an option for vaccination of healthy, nonpregnant
persons aged 5–49 years who want to avoid influenza, and
those who might be in close contact with persons at high risk
for severe complications, including health-care workers. Dur-
ing periods when inactivated vaccine is in short supply, use of
LAIV is encouraged when feasible for eligible persons (in-
cluding health-care workers) because use of LAIV by these
persons might increase availability of inactivated vaccine for
persons in groups at high risk. Possible advantages of LAIV
include its potential to induce a broad mucosal and systemic
immune response, its ease of administration, and the accept-
ability of an intranasal rather than intramuscular route of
administration.
LAIV Dosage and Administration
LAIV is intended for intranasal administration only and
should not be administered by the intramuscular, intrader-
mal, or intravenous route. LAIV must be thawed before ad-
ministration. This can be accomplished by holding an
individual sprayer in the palm of the hand until thawed, with
subsequent immediate administration. Alternatively, the vac-
cine can be thawed in a refrigerator and stored at 2ºC–8ºC
for <60 hours before use. Vaccine should not be refrozen after
thawing. LAIV is supplied in a prefilled single-use sprayer
containing 0.5 mL of vaccine. Approximately 0.25 mL (i.e.,
half of the total sprayer contents) is sprayed into the first nos-
tril while the recipient is in the upright position. An attached
dose-divider clip is removed from the sprayer to administer
the second half of the dose into the other nostril. If the vac-
cine recipient sneezes after administration, the dose should
not be repeated.
LAIV should be administered annually according to the
following schedule:
• Children aged 5–<9 years previously unvaccinated at any
time with either LAIV or inactivated influenza vaccine
should receive 2 doses* of LAIV separated by 6–10 weeks;
if possible, the second dose of vaccine should be admin-
istered before the onset of influenza season.
• Children aged 5–<9 years previously vaccinated at any time
with either LAIV or inactivated influenza vaccine should
receive 1 dose of LAIV. They do not require a second dose.
• Persons aged 9–49 years should receive 1 dose of LAIV.
LAIV can be administered to persons with minor acute ill-
nesses (e.g., diarrhea or mild upper respiratory tract infection
with or without fever). However, if clinical judgment indi-
cates nasal congestion is present that might impede delivery
of the vaccine to the nasopharyngeal mucosa, deferral of ad-
ministration should be considered until resolution of the
illness.
Whether concurrent administration of LAIV with other
vaccines affects the safety or efficacy of either LAIV or the
simultaneously administered vaccine is unknown. In the ab-
sence of specific data indicating interference, following the
ACIP general recommendations for immunization is prudent
(210). Inactivated vaccines do not interfere with the immune
response to other inactivated vaccines or to live vaccines. In-
activated or live vaccines can be administered simultaneously
with LAIV. However, after administration of a live vaccine, at
least 4 weeks should pass before another live vaccine is admin-
istered (see Persons Who Should Not Be Vaccinated with LAIV).
LAIV and Use of Influenza Antiviral
Medications
The effect on safety and efficacy of LAIV coadministration
with influenza antiviral medications has not been studied.
However, because influenza antivirals reduce replication of
influenza viruses, LAIV should not be administered until 48
hours after cessation of influenza antiviral therapy, and influ-
enza antiviral medications should not be administered for 2
weeks after receipt of LAIV.
LAIV Storage
LAIV must be stored at -15ºC or colder. A manufacturer-
supplied freezer box was formerly required for storage of LAIV
in a frost-free freezer; however, the freezer box is now optional,
and LAIV may now be stored in frost-free freezers without us-
ing a freezer box. LAIV can be thawed in a refrigerator and
stored at 2ºC–8ºC for <60 hours before use. It should not be
refrozen after thawing because of decreased vaccine potency.
* One dose equals 0.5 mL, divided equally between each nostril.
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Shedding, Transmission, and Stability
of Vaccine Viruses
Available data indicate that both children and adults vacci-
nated with LAIV can shed vaccine viruses for >2 days after
vaccination, although in lower titers than typically occur with
shedding of wild-type influenza viruses. Shedding should not
be equated with person-to-person transmission of vaccine vi-
ruses, although, in rare instances, shed vaccine viruses can be
transmitted from vaccinees to nonvaccinated persons.
One unpublished study of a child care center setting
assessed transmissibility of vaccine viruses from 98 vaccinated
to 99 unvaccinated children, all aged 8–36 months. Eighty
percent of vaccine recipients shed one or more virus strains,
with a mean of 7.6 days’ duration (249). One vaccine type
influenza type B isolate was recovered from a placebo recipi-
ent and was confirmed to be vaccine-type virus. The type B
isolate retained the cold-adapted, temperature-sensitive, at-
tenuated phenotype, and it possessed the same genetic se-
quence as a virus shed from a vaccine recipient in the same
children’s play group. The placebo recipient from whom the
influenza type B vaccine virus was isolated did not exhibit
symptoms that were different from those experienced by vac-
cine recipients. The estimated probability of acquiring vac-
cine virus after close contact with a single LAIV recipient in
this child care population was 0.58%–2.4%.
One study assessing shedding of vaccine viruses in 20 healthy
vaccinated adults aged 18–49 years demonstrated that the
majority of shedding occurred within the first 3 days after
vaccination, although one participant was noted to shed
virus on day 7 after vaccine receipt. No study participants
shed vaccine viruses >10 days after vaccination. Duration or
type of symptoms associated with receipt of LAIV did not
correlate with duration of shedding vaccine viruses. Person-
to-person transmission of vaccine viruses was not assessed in
this study (250).
Another study assessing shedding of vaccine viruses in 14
healthy adults aged 18–49 years indicated that 50% of these
adults had viral antigen detected by direct immunofluorescence
or rapid antigen tests within 7 days of vaccination. The major-
ity of viral shedding was detected on day 2 or 3. Person-to-
person transmission of vaccine viruses was not assessed in this
study (251).
In clinical trials, viruses shed by vaccine recipients have been
phenotypically stable. In one study, nasal and throat swab
specimens were collected from 17 study participants for 2
weeks after vaccine receipt (252). Virus isolates were analyzed
by multiple genetic techniques. All isolates retained the LAIV
genotype after replication in the human host, and all retained
the cold-adapted and temperature-sensitive phenotypes. A
study conducted in a day care setting found that limited ge-
netic change occurred in the LAIV strains after replication in
the vaccine recipients (253).
LAIV Side Effects and Adverse Reactions
Twenty prelicensure clinical trials assessed the safety of the
approved LAIV. In these combined studies, approximately
28,000 doses of the vaccine were administered to approxi-
mately 20,000 persons. A subset of these trials were random-
ized, placebo-controlled studies in which an estimated 4,000
healthy children aged 5–17 years and 2,000 healthy adults
aged 18–49 years were vaccinated. The incidence of adverse
events possibly complicating influenza (e.g., pneumonia, bron-
chitis, bronchiolitis, or central nervous system events) was
not statistically different among LAIV and placebo recipients
aged 5–49 years. LAIV is made from attenuated viruses and
does not cause influenza in vaccine recipients.
Children. In a subset of healthy children aged 60–71
months from one clinical trial (111,112), certain signs and
symptoms were reported more often among LAIV recipients
after the first dose (n = 214) than placebo recipients (n = 95)
(e.g., runny nose, 48.1% versus 44.2%; headache, 17.8% ver-
sus 11.6%; vomiting, 4.7% versus 3.2%; and myalgias, 6.1%
versus 4.2%), but these differences were not statistically sig-
nificant. In other trials, signs and symptoms reported after
LAIV administration have included runny nose or nasal con-
gestion (20%–75%), headache (2%–46%), fever (0–26%),
vomiting (3%–13%), abdominal pain (2%), and myalgias (0–
21%) (105,108,110,254–256). These symptoms were asso-
ciated more often with the first dose and were self-limited.
Data from a study of children aged 1–17 years indicated an
increase in asthma or reactive airways disease in the subset
aged 1–<5 years (257,258). Because of these data, LAIV is
not approved for use among children aged <5 years. Another
study was conducted among more than 11,000 children aged
18 months–18 years in which 18,780 doses of vaccine were
administered over a 4-year period. This study did not observe
an increase in asthma visits 0–15 days after vaccination for
children who were aged 18 months–4 years compared with
the prevaccination period; however, a significant increase in
asthma events was observed 15–42 days after vaccination but
only in vaccine year 1 (259).
Adults. Among adults, runny nose or nasal congestion
(28%–78%), headache (16%–44%), and sore throat (15%–
27%) have been reported more often among vaccine recipi-
ents than placebo recipients (114,260,261). In one clinical
trial (114) among a subset of healthy adults aged 18–49 years,
signs and symptoms reported more frequently among LAIV
recipients (n = 2,548) than placebo recipients (n = 1,290)
within 7 days after each dose included cough (13.9% versus
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10.8%), runny nose (44.5% versus 27.1%), sore throat (27.8%
versus 17.1%), chills (8.6% versus 6.0%), and tiredness/
weakness (25.7% versus 21.6%).
Safety Among Groups at High Risk from Influenza-
Related Morbidity. Until additional data are acquired and
analyzed, persons at high risk for experiencing complications
from influenza virus infection (e.g., immunocompromised
patients; patients with asthma, cystic fibrosis, or chronic ob-
structive pulmonary disease; or persons aged >65 years) should
not be vaccinated with LAIV. Protection from influenza among
these groups should be accomplished using inactivated influ-
enza vaccine.
Serious Adverse Events. Serious adverse events requiring
medical attention among healthy children aged 5–17 years or
healthy adults aged 18–49 years occurred at a rate of <1%.
Surveillance will continue for adverse events that might not
have been detected in previous studies. Reviews of reports to
VAERS after vaccination of approximately 2,500,000 per-
sons during the 2003–04 and 2004–05 influenza seasons did
not reveal any substantial new safety concerns (262,263).
Health-care professionals should promptly report all clini-
cally significant adverse events after LAIV administration to
VAERS, as recommended for inactivated influenza vaccine.
Persons Who Should Not Be Vaccinated
with LAIV
The following populations should not be vaccinated with
LAIV:
• persons aged <5 years or those aged >50 years;†
• persons with asthma, reactive airways disease, or other
chronic disorders of the pulmonary or cardiovascular sys-
tems; persons with other underlying medical conditions,
including such metabolic diseases as diabetes, renal dys-
function, and hemoglobinopathies; or persons with
known or suspected immunodeficiency diseases or who
are receiving immunosuppressive therapies;†
• children or adolescents receiving aspirin or other salicy-
lates (because of the association of Reye syndrome with
wild-type influenza virus infection);†
• persons with a history of GBS;
• pregnant women;† or
• persons with a history of hypersensitivity, including ana-
phylaxis, to any of the components of LAIV or to eggs.
Vaccination of Close Contacts of Persons
at High Risk for Complications from Influenza
Close contacts of persons at high risk for complications
from influenza should receive influenza vaccine to reduce
transmission of wild-type influenza viruses to persons at high
risk. Use of inactivated influenza vaccine is preferred for vac-
cinating household members, health-care workers, and oth-
ers who have close contact with severely immunocompromised
persons (e.g., patients with hematopoietic stem cell trans-
plants) during those periods in which the
immunocompromised person requires care in a protective
environment. The rationale for not using LAIV among health-
care workers caring for such patients is the theoretical risk
that a live, attenuated vaccine virus could be transmitted to
the severely immunocompromised person. If a health-care
worker receives LAIV, that worker should refrain from con-
tact with severely immunocompromised patients for 7 days
after vaccine receipt. Hospital visitors who have received LAIV
should refrain from contact with severely
immunocompromised persons for 7 days after vaccination;
however, such persons need not be excluded from visitation
of patients who are not severely immunocompromised. ACIP
has not indicated a preference for inactivated influenza vac-
cine use by health-care workers or other persons who have
close contact with persons with lesser degrees of immunodefi-
ciency (e.g., persons with diabetes, persons with asthma tak-
ing corticosteroids, or persons infected with HIV) or for
inactivated influenza vaccine use by health-care workers or
other healthy persons aged 5–49 years in close contact with
all other groups at high risk.
Personnel Who May Administer LAIV
Low-level introduction of vaccine viruses into the environ-
ment is likely unavoidable when administering LAIV. The
risk for acquiring vaccine viruses from the environment is
unknown but likely to be limited. Severely
immunocompromised persons should not administer LAIV.
However, other persons at high risk for influenza complica-
tions may administer LAIV. These include persons with un-
derlying medical conditions placing them at high risk or who
are likely to be at risk, including pregnant women, persons
with asthma, and persons aged >50 years.
Recommended Vaccines for Different
Age Groups
When vaccinating children aged 6 months–3 years, health-
care providers should use inactivated influenza vaccine that
has been approved by FDA for this age group. Inactivated
influenza vaccine from sanofi pasteur (Fluzone) is approved
for use among persons aged >6 months. Inactivated influenza
vaccine from Novartis, formerly Chiron (Fluvirin), is labeled
in the United States for use among persons aged >4 years
because data to demonstrate efficacy among younger persons† These persons should receive inactivated influenza vaccine.
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have not been provided to FDA, whereas inactivated influ-
enza vaccine from GlaxoSmithKline (FLUARIX) is labeled
for use in persons aged >18 years. LAIV from MedImmune
(FluMist) is approved for use by healthy persons aged 5–49
years (Table 4).
Influenza Vaccine Supply and Timing
of Annual Influenza Vaccination
The annual supply of influenza vaccine and the timing of
its distribution cannot be guaranteed in any year. Currently,
influenza vaccine manufacturers are projecting that approxi-
mately 100 million doses of influenza vaccine will be avail-
able in the United States for the 2006–07 influenza season,
an amount that is approximately 16% more doses than were
available for the 2005–06 season. An additional 15 million–
20 million doses might be available if a new vaccine is licensed
in 2006. (Information about the status of licensure of new vac-
cines is available at http://aapredbook.aappublications.org/
news/vaccstatus.pdf.) However, influenza vaccine distribution
delays or vaccine shortages remain possible in part because of
the inherent critical time constraints in manufacturing the
vaccine given the annual updating of the influenza vaccine
strains. To ensure optimal use of available doses of influenza
vaccine, health-care providers, those planning organized cam-
paigns, and state and local public health agencies should
1) develop plans for expanding outreach and infrastructure
to vaccinate more persons than last year and
2) develop contingency plans for the timing and
prioritization of administering influenza vaccine, if the
supply of vaccine is delayed and/or reduced.
CDC and other public health agencies will assess the vac-
cine supply on a continuing basis throughout the manufac-
turing period and will inform both providers and the general
public if a substantial delay or an inadequate supply occurs.
Because LAIV is approved for use in healthy persons aged 5–
49 years, no recommendations exist for limiting the timing
and prioritization of administering LAIV. Administration of
LAIV is encouraged as soon as it is available and throughout
the season.
If the supply of inactivated influenza vaccine is adequate
and a sufficient number of doses will be available beginning
in September, vaccination efforts should be structured to en-
sure the vaccination of as many persons as possible over the
course of several months. Even if vaccine distribution begins
in September, distribution probably will not be completed
until December or January; therefore, the following recom-
mendations reflect this phased distribution during the months
of October, November, and December, and possibly later. The
prioritized (tiered) use of influenza vaccine during inactivated
influenza vaccine shortages applies only to the use of inacti-
vated vaccine and not to LAIV. When feasible, during short-
ages of inactivated influenza vaccine, LAIV should be used
preferentially for all healthy persons aged 5–49 years (includ-
ing health-care workers) to increase the availability of inacti-
vated vaccine for groups at high risk.
The following section provides guidance regarding the tim-
ing of vaccination under two scenarios: 1) if the supply of
inactivated influenza vaccine is adequate, and 2) if a reduced
or delayed supply of inactivated vaccine occurs.




To avoid missed opportunities for vaccination of persons
at increased risk for serious complications and their house-
hold contacts (including out-of-home caregivers and house-
hold contacts of children aged 0–59 months), such persons
should be offered vaccine beginning in September during rou-
tine health-care visits or during hospitalizations, if vaccine is
available. However, in facilities housing older persons (e.g.,
nursing homes), vaccination before October typically should
be avoided because antibody levels in such persons can begin
to decline more rapidly after vaccination (264). If vaccine
supplies are sufficient, vaccination of other persons also may
begin before October.
In addition, because children aged 6 months–<9 years who
have not been previously vaccinated need 2 doses of vaccine,
they should receive their first dose in September, if vaccine is
available, so that both doses can be administered before the
onset of influenza activity. For previously vaccinated children,
only 1 dose is needed.
Vaccination in October and November
The optimal time for vaccination efforts is usually during
October–November. In October, vaccination in provider-
based settings should start or continue for all patients—both
high risk and healthy—and extend throughout November.
Vaccination of children aged 6 months–<9 years who are re-
ceiving vaccine for the first time should also begin in Octo-
ber, if not done earlier, because those children need a booster
dose 4–10 weeks after the initial dose, depending upon
whether they are receiving inactivated influenza vaccine or
LAIV.
If supplies of inactivated influenza vaccine are not adequate,
ACIP recommends that vaccine providers focus their vacci-
nation efforts in October, primarily on persons aged >50 years,
persons aged <50 years at increased risk for influenza-related
complications (including children aged 6–59 months), house-
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hold contacts of persons at high risk (including out-of-home
caregivers and household contacts of children aged 0–59
months), and health-care workers (178). Efforts to vaccinate
other persons who wish to decrease their risk for influenza
virus infection should not begin until November; however, if
such persons request vaccination in October, vaccination
should not be deferred, unless vaccine supplies dictate other-
wise.
Vaccination in December and Later
When inactivated vaccine is delayed, a substantial propor-
tion of doses often do not become available until December
or later. Nevertheless, even when supply is not delayed or re-
duced, as demonstrated by the relatively low vaccination cov-
erage levels among persons in the defined priority groups,
many persons who should receive influenza vaccine remain
unvaccinated (Table 3).
Providers should routinely offer influenza vaccine through-
out the influenza season even after influenza activity has been
documented in the community. In the United States, seasonal
influenza activity can begin to increase as early as October or
November, but influenza activity has not reached peak levels
until late December–early March in the majority of recent
seasons (Table 5). Although the timing of influenza activity
can vary by region, vaccine administered after November is
likely to be beneficial in the majority of influenza seasons.
Adults have peak antibody protection against influenza virus
infection 2 weeks after vaccination (265,266).
Timing of Organized Vaccination Campaigns
Persons and institutions planning substantial organized vac-
cination campaigns (e.g., health departments, occupational
health clinics, and community vaccinators) should consider
scheduling these events after at least mid-October because
the availability of vaccine in any location cannot be ensured
consistently in early fall. Scheduling campaigns after mid-
October will minimize the need for cancellations because vac-
cine is unavailable. These vaccination clinics should be
scheduled through November, with attention to settings that
serve children aged 6–59 months, pregnant women, other
persons aged <50 years at increased risk for influenza-related
complications, persons aged >50 years, health-care workers,
and household contacts and out-of-home caregivers of per-
sons at high risk (including children aged 0–59 months) to
the extent feasible. Planners are encouraged to schedule at
least one vaccination clinic in December.
During a vaccine shortage or delay, substantial proportions
of inactivated influenza vaccine doses may not be released
until November and December or later. Beginning in
November, vaccination campaigns can be broadened to in-
clude healthy persons who wish to reduce their risk for influ-
enza virus infection. ACIP recommends organizers schedule
these vaccination clinics throughout November and Decem-
ber. When the vaccine is significantly delayed, agencies should
consider offering vaccination clinics into January as long as
vaccine supplies are available. Campaigns using LAIV are





Successful vaccination programs combine publicity and
education for health-care workers and other potential vac-
cine recipients, a plan for identifying persons at high risk, use
of reminder/recall systems, assessment of practice-level vacci-
nation rates with feedback to staff, and efforts to remove ad-
ministrative and financial barriers that prevent persons from
receiving the vaccine, including use of standing orders pro-
grams (19,267). Since October 2005, the Centers for
Medicare and Medicaid Services (CMS) has required nursing
homes participating in the Medicare and Medicaid programs
to offer all residents influenza and pneumococcal vaccines
and to document the results. According to the requirements,
each resident is to be vaccinated unless it is medically con-
traindicated or the resident or his/her legal representative re-
fuses vaccination. This information is to be reported as part
of the CMS Minimum Data Set, which tracks nursing home
health parameters (268).
The use of standing orders programs by long-term–care fa-
cilities (e.g., nursing homes and skilled nursing facilities),
hospitals, and home health agencies might help to ensure the
administration of recommended vaccinations for adults (269).
Standing orders programs for both influenza and pneumo-
coccal vaccination should be conducted under the supervi-
sion of a licensed practitioner according to a
TABLE 5. Month of peak influenza activity* during 30 influenza seasons — United States, 1976–2006
Month
Nov Dec Jan Feb Mar Apr May
No. (%) of years with peak influenza activity 1 (3) 4 (13) 6 (20) 13 (43) 4 (13) 1 (3) 1 (3)
* The peak week of activity was defined as the week with the greatest percentage of respiratory specimens testing positive for influenza on the basis of a
3-week moving average. Laboratory data were provided by U.S. World Health Organization Collaborating Centers (CDC, unpublished data, 1976–2006).
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physician-approved facility or agency policy by health-care
workers trained to screen patients for contraindications to
vaccination, administer vaccine, and monitor for adverse
events. CMS has removed the physician signature require-
ment for the administration of influenza and pneumococcal
vaccines to Medicare and Medicaid patients in hospitals, long-
term–care facilities, and home health agencies (269). To the
extent allowed by local and state law, these facilities and agen-
cies may implement standing orders for influenza and pneu-
mococcal vaccination of Medicare- and Medicaid-eligible
patients. Other settings (e.g., outpatient facilities, managed
care organizations, assisted living facilities, correctional fa-
cilities, pharmacies, and adult workplaces) are encouraged to
introduce standing orders programs as well (20). In addition,
physician reminders (e.g., flagging charts) and patient remind-
ers are recognized strategies for increasing rates of influenza
vaccination. Persons for whom influenza vaccine is recom-
mended can be identified and vaccinated in the settings de-
scribed in the following sections.
Outpatient Facilities Providing Ongoing Care
Staff in facilities providing ongoing medical care (e.g., phy-
sicians’ offices, public health clinics, employee health clinics,
hemodialysis centers, hospital specialty-care clinics, and out-
patient rehabilitation programs) should identify and label the
medical records of patients who should receive vaccination.
Vaccine should be offered during visits beginning in
September (if vaccine is available) and throughout the influ-
enza season. The offer of vaccination and its receipt or refusal
should be documented in the medical record. Patients for
whom vaccination is recommended and who do not have regu-
larly scheduled visits during the fall should be reminded by
mail, telephone, or other means of the need for vaccination.
Outpatient Facilities Providing Episodic
or Acute Care
Beginning each September, acute health-care facilities (e.g.,
emergency departments and walk-in clinics) should offer vac-
cinations to persons for whom vaccination is recommended
or provide written information regarding why, where, and
how to obtain the vaccine. This written information should
be available in languages appropriate for the populations served
by the facility.
Nursing Homes and Other Residential Long-
Term–Care Facilities
During October and November each year, vaccination
should be routinely provided to all residents of chronic-care
facilities with the concurrence of attending physicians. Con-
sent for vaccination should be obtained from the resident or
a family member at the time of admission to the facility or
anytime afterwards. Ideally, all residents should be vaccinated
at one time, before influenza season. Residents admitted
through March after completion of the vaccination program
at the facility should be vaccinated at the time of admission.
Acute-Care Hospitals
Persons of all ages (including children) with high-risk con-
ditions and persons aged >50 years who are hospitalized at
any time during September–March should be offered and
strongly encouraged to receive influenza vaccine before they
are discharged if they have not already received the vaccine
during that season. In one study, 39%–46% of adult patients
hospitalized during the winter with influenza-related diag-
noses had been hospitalized during the preceding fall (270).
Thus, the hospital serves as a setting in which persons at in-
creased risk for subsequent hospitalization can be identified
and vaccinated. However, vaccination of persons at high risk
during or after their hospitalizations is often not done. In a
study of hospitalized Medicare patients, only 31.6% were
vaccinated before admission, 1.9% during admission, and
10.6% after admission (271). Using standing orders in hos-
pitals increases vaccination rates among hospitalized persons
(272).
Visiting Nurses and Others Providing
Home Care to Persons at High Risk
Beginning in September, nursing-care plans should iden-
tify patients for whom vaccination is recommended, and vac-
cine should be administered in the home, if necessary.
Caregivers and other persons in the household (including
children) should be referred for vaccination.
Other Facilities Providing Services to Persons
Aged >50 Years
Beginning in October, such facilities as assisted living hous-
ing, retirement communities, and recreation centers should
offer unvaccinated residents and attendees vaccination on-
site before the start of the influenza season. Staff education
should emphasize the need for influenza vaccine.
Health-Care Workers
Beginning in October each year, health-care facilities should
offer influenza vaccinations to all workers, including night
and weekend staff. Particular emphasis should be placed on
providing vaccinations to persons who care for members of
groups at high risk. Efforts should be made to educate health-
care workers regarding the benefits of vaccination and the
potential health consequences of influenza illness for their
patients, themselves, and their family members. All health-
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care workers should be provided convenient access to influ-
enza vaccine at the work site, free of charge, as part of em-
ployee health programs (146,177,179).
Future Directions for Research
and Recommendations Related
to Influenza Vaccine
 The relatively low effectiveness of influenza vaccine admin-
istered to older adults highlights the need for more immuno-
genic influenza vaccines for the elderly (273) and the need for
additional research to understand potential biases in estimat-
ing the benefits of vaccination among older adults in reduc-
ing hospitalizations and deaths (274–276). Additional studies
of the relative cost-effectiveness and cost utility of influenza
vaccination among children and adults, especially those aged
<65 years, are needed and should be designed to account for
year-to-year variations in influenza attack rates, illness sever-
ity, hospitalization costs and rates, and vaccine effectiveness
(277). Additional data also are needed to quantify the ben-
efits of influenza vaccination of health-care workers in pro-
tecting their patients (278). Furthermore, larger consortia of
networks are needed that are able to assess rare events that
occur after vaccination, including GBS.
ACIP continues to review new vaccination strategies to pro-
tect against influenza, including the possibility of expanding
routine influenza vaccination recommendations toward uni-
versal vaccination or other approaches that will help greatly
reduce or prevent the transmission of influenza (279–282). In
addition, as noted by the National Vaccine Advisory Commit-
tee, strengthening the U.S. influenza vaccination system will
require improving vaccine financing, increasing demand, and
implementing systems to help better understand the burden of
influenza in the United States (283). Strategies to evaluate the
effect of vaccination recommendations remain critical.
Recommendations for Using
Antiviral Agents for Influenza
Although annual vaccination is the primary strategy for
preventing complications of influenza virus infections, anti-
viral medications with activity against influenza viruses can
be effective for the chemoprophylaxis and treatment of influ-
enza. Four licensed influenza antiviral agents are available in
the United States: amantadine, rimantadine, zanamivir, and
oseltamivir. Influenza A virus resistance to amantadine and
rimantadine can emerge rapidly during treatment. On the
basis of antiviral testing results conducted at CDC and in
Canada indicating high levels of resistance (23,24,284), ACIP
recommends that neither amantadine nor rimantadine be used
for the treatment or chemoprophylaxis of influenza A in the
United States until susceptibility to these antiviral medica-
tions has been re-established among circulating influenza A
viruses. Oseltamivir or zanamivir can be prescribed if antivi-
ral treatment of influenza is indicated. Oseltamivir is approved
for treatment of persons aged >1 year, and zanamivir is ap-
proved for treatment of persons aged >7 years. Oseltamivir
and zanamivir can be used for chemoprophylaxis of influ-
enza; oseltamivir is licensed for use in persons aged >1 year,
and zanamivir is licensed for use in persons aged >5 years.
Antiviral Agents for Influenza
Zanamivir and oseltamivir are chemically related antiviral
drugs known as neuraminidase inhibitors that have activity
against both influenza A and B viruses. Both zanamivir and
oseltamivir were approved in 1999 for treatment of uncom-
plicated influenza virus infections. In 2000, oseltamivir was
approved for chemoprophylaxis of influenza among persons
aged >13 years and was approved for chemoprophylaxis of
children aged >1 year in 2005. In 2006, zanamivir was ap-
proved for chemoprophylaxis of children aged >5 years.
The two drugs differ in pharmacokinetics, side effects, routes
of administration, approved age groups, dosages, and costs.
An overview of the indications, use, administration, and
known primary side effects of these medications is presented
in the following sections. Package inserts should be consulted
for additional information. Detailed information regarding
amantadine and rimantadine is available in the previous pub-
lication of the ACIP influenza recommendations (285).
Role of Laboratory Diagnosis
Appropriate treatment of patients with respiratory illness
depends on accurate and timely diagnosis. Influenza surveil-
lance information and diagnostic testing can aid clinical judg-
ment and help guide treatment decisions. For example, early
diagnosis of influenza can reduce the inappropriate use of anti-
biotics and provide the option of using antiviral therapy. How-
ever, because certain bacterial infections can produce symptoms
similar to influenza, bacterial infections should be considered
and appropriately treated, if suspected. In addition, bacterial
infections can occur as a complication of influenza.
The accuracy of clinical diagnosis of influenza on the basis
of symptoms alone is limited because symptoms from illness
caused by other pathogens can overlap considerably with in-
fluenza (33,42,43). Because testing all patients who might
have influenza is not feasible, influenza surveillance by state
and local health departments and CDC can provide informa-
tion regarding the presence of influenza viruses in the com-
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munity. Surveillance also can identify the predominant cir-
culating types, influenza A subtypes, and strains of influenza
viruses.
Diagnostic tests available for influenza include viral cul-
ture, serology, rapid antigen testing, polymerase chain reac-
tion (PCR), and immunofluorescence assays (28). The
sensitivity and specificity of any test for influenza can vary by
the laboratory that performs the test, the type of test used, the
type of specimen tested, and the timing of specimen collec-
tion. Among respiratory specimens for viral isolation or rapid
detection, nasopharyngeal specimens are typically more ef-
fective than throat swab specimens (286). As with any diag-
nostic test, results should be evaluated in the context of other
clinical and epidemiologic information available to health-
care providers.
Commercial rapid diagnostic tests are available that can
detect influenza viruses in 30 minutes (28,287). Some tests
are approved for use in any outpatient setting, whereas others
must be used in a moderately complex clinical laboratory.
These rapid tests differ in the types of influenza viruses they
can detect and whether they can distinguish between influ-
enza types. Different tests can detect 1) only influenza A vi-
ruses; 2) both influenza A and B viruses, but not distinguish
between the two types; or 3) both influenza A and B and
distinguish between the two.
None of the rapid tests provide any information regarding
influenza A subtypes. The types of specimens acceptable for
use (i.e., throat, nasopharyngeal, or nasal; and aspirates, swabs,
or washes) also vary by test. The specificity and, in particular,
the sensitivity of rapid tests are lower than for viral culture
and vary by test (288,289). Because of the lower sensitivity of
the rapid tests, physicians should consider confirming nega-
tive tests with viral culture or other means because of the pos-
sibility of false-negative rapid test results, especially during
periods of peak community influenza activity. In contrast,
false-positive rapid test results are less likely but can occur
during periods of low influenza activity. Therefore, when in-
terpreting results of a rapid influenza test, physicians should
consider the positive and negative predictive values of the test
in the context of the level of influenza activity in their com-
munity. Package inserts and the laboratory performing the
test should be consulted for more details regarding use of rapid
diagnostic tests. Additional information concerning diagnos-
tic testing is available at http://www.cdc.gov/flu/professionals/
labdiagnosis.htm.
Despite the availability of rapid diagnostic tests, collecting
clinical specimens for viral culture is critical because only
culture isolates can provide specific information regarding
circulating strains and subtypes of influenza viruses. This in-
formation is needed to compare current circulating influenza
strains with vaccine strains, to guide decisions regarding in-
fluenza treatment and chemoprophylaxis, and to formulate
vaccine for the coming year. Virus isolates also are needed to
monitor the emergence of antiviral resistance and the emer-




CDC recently reported that 193 (92%) of 209 influenza A
(H3N2) viruses isolated from patients in 26 states demon-
strated a change at amino acid 31 in the M2 gene that confers
resistance to adamantanes (23,24). In addition, two of eight
influenza A (H1N1) viruses tested were resistant (24). Cana-
dian health authorities also have reported the same mutation
in a comparable proportion of isolates recently tested (284).
Until these findings, previous screenings of epidemic strains
of influenza A viruses found few amantadine- and
rimantadine-resistant viruses (290–292).
Viral resistance to adamantanes can emerge rapidly during
treatment because a single point mutation at amino acid po-
sitions 26, 27, 30, 31, or 34 of the M2 protein can confer
cross resistance to both amantadine and rimantadine
(293,294). Drug-resistant viruses can emerge in approximately
one third of patients when either amantadine or rimantadine
is used for therapy (293,295,296). During the course of aman-
tadine or rimantadine therapy, resistant influenza strains can
replace susceptible strains within 2–3 days of starting therapy
(290,297). Resistant viruses have been isolated from persons
who live at home or in an institution in which other residents
are taking or have taken amantadine or rimantadine as therapy
(298,299); however, the frequency with which resistant vi-
ruses are transmitted and their effect on efforts to control
influenza are unknown.
Persons who have influenza A virus infection and who are
treated with either amantadine or rimantadine can shed sus-
ceptible viruses early in the course of treatment and later shed
drug-resistant viruses, including after 5–7 days of therapy (295).
Resistance to zanamivir and oseltamivir can be induced in
influenza A and B viruses in vitro (300–307), but induction
of resistance usually requires multiple passages in cell culture.
By contrast, resistance to amantadine and rimantadine in vitro
can be induced with fewer passages in cell culture (308,309).
Development of viral resistance to zanamivir and oseltamivir
during treatment has been identified but does not appear to
be frequent (310–314). In one pediatric study, 5.5% of pa-
tients treated with oseltamivir had posttreatment isolates that
were resistant to neuraminidase inhibitors. One small study
of Japanese children treated with oseltamivir reported a high
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frequency of resistant viruses (315). However, no transmis-
sion of neuraminidase inhibitor-resistant viruses in humans
has been documented to date. No isolates with reduced sus-
ceptibility to zanamivir have been reported from clinical tri-
als, although the number of posttreatment isolates tested is
limited (316), and the risk for emergence of zanamivir-
resistant isolates cannot be quantified (317). Only one clini-
cal isolate with reduced susceptibility to zanamivir, obtained
from an immunocompromised child on prolonged therapy,
has been reported (312). Available diagnostic tests are not opti-
mal for detecting clinical resistance to the neuraminidase in-
hibitor antiviral drugs, and additional tests are being developed
(316,318). Postmarketing surveillance for neuraminidase
inhibitor-resistant influenza viruses is being conducted (319).
Indications for Use of Antivirals
When Susceptibility Exists
Treatment
When administered within 2 days of illness onset to other-
wise healthy adults, zanamivir and oseltamivir can reduce the
duration of uncomplicated influenza A and B illness by ap-
proximately 1 day compared with placebo (91,320–334).
More clinical data are available concerning the efficacy of
zanamivir and oseltamivir for treatment of influenza A virus
infection than for treatment of influenza B virus infection
(324,335–344). However, in vitro data and studies of treat-
ment among mice and ferrets (345–352), in addition to clinical
studies, have documented that zanamivir and oseltamivir have
activity against influenza B viruses (310,317,325,329,353,354).
Data are limited regarding the effectiveness of the antiviral
agents in preventing serious influenza-related complications
(e.g., bacterial or viral pneumonia or exacerbation of chronic
diseases). Evidence for the effectiveness of these antiviral drugs
is principally based on studies of patients with uncomplicated
influenza (355). Data are limited concerning the effective-
ness of zanamivir and oseltamivir for treatment of influenza
among persons at high risk for serious complications of in-
fluenza (31,321,322,324,325,330–338). Among influenza vi-
rus infected participants in 10 clinical trials, the risk for
pneumonia among those participants receiving oseltamivir
was approximately 50% lower than among those persons re-
ceiving a placebo (339). A similar significant reduction was
also found for hospital admissions; a 50% reduction was ob-
served in the small subset of high-risk participants, although
this reduction was not statistically significant. Fewer studies
of the efficacy of influenza antivirals have been conducted
among pediatric populations (295,322,328,329). One study
of oseltamivir treatment documented a decreased incidence
of otitis media among children (323). Inadequate data exist
regarding the safety and efficacy of any of the influenza anti-
viral drugs for use among children aged <1 year (289).
Initiation of antiviral treatment within 2 days of illness onset
is recommended. The recommended duration of treatment
with either zanamivir or oseltamivir is 5 days.
Chemoprophylaxis
Chemoprophylactic drugs are not a substitute for vaccina-
tion, although they are critical adjuncts in preventing and
controlling influenza. In community studies of healthy adults,
both oseltamivir and zanamivir are similarly effective in pre-
venting febrile, laboratory-confirmed influenza illness (effi-
cacy: zanamivir, 84%; oseltamivir, 82%) (324,340,356). Both
antiviral agents also have been reported to prevent influenza
illness among persons administered chemoprophylaxis after a
household member had influenza diagnosed (341,353,356).
Experience with chemoprophylactic use of these agents in in-
stitutional settings or among patients with chronic medical
conditions is limited in comparison with the adamantanes
(310,337,338,342–344). One 6-week study of oseltamivir
chemoprophylaxis among nursing home residents reported a
92% reduction in influenza illness (310,357). Use of zanamivir
has not been reported to impair the immunologic response to
influenza vaccine (317,358). Data are not available regarding
the efficacy of any of the four antiviral agents in preventing
influenza among severely immunocompromised persons.
When determining the timing and duration for adminis-
tering influenza antiviral medications for chemoprophylaxis,
factors related to cost, compliance, and potential side effects
should be considered. To be maximally effective as chemo-
prophylaxis, the drug must be taken each day for the dura-
tion of influenza activity in the community.
Persons at High Risk Who Are Vaccinated After Influ-
enza Activity Has Begun. Persons at high risk for complica-
tions of influenza still can be vaccinated after an outbreak of
influenza has begun in a community. However, development
of antibodies in adults after vaccination takes approximately
2 weeks (265,266). When influenza vaccine is administered
while influenza viruses are circulating, chemoprophylaxis
should be considered for persons at high risk during the time
from vaccination until immunity has developed. Children
aged <9 years who receive influenza vaccine for the first time
can require 6 weeks of chemoprophylaxis (i.e., chemopro-
phylaxis for 4 weeks after the first dose of vaccine and an
additional 2 weeks of chemoprophylaxis after the second dose).
Persons Who Provide Care to Those at High Risk. To
reduce the spread of virus to persons at high risk during com-
munity or institutional outbreaks, chemoprophylaxis during
peak influenza activity can be considered for unvaccinated
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persons who have frequent contact with persons at high risk.
Persons with frequent contact include employees of hospi-
tals, clinics, and chronic-care facilities; household members;
visiting nurses; and volunteer workers. If an outbreak is caused
by a strain of influenza that might not be covered by the vac-
cine, chemoprophylaxis should be considered for all such
persons, regardless of their vaccination status.
Persons Who Have Immune Deficiencies. Chemopro-
phylaxis can be considered for persons at high risk who are
expected to have an inadequate antibody response to influ-
enza vaccine. This category includes persons infected with
HIV, chiefly those with advanced HIV disease. No published
data are available concerning possible efficacy of chemopro-
phylaxis among persons with HIV infection or interactions
with other drugs used to manage HIV infection. Such pa-
tients should be monitored closely if chemoprophylaxis is ad-
ministered.
Other Persons. Chemoprophylaxis throughout the influ-
enza season or during peak influenza activity might be appro-
priate for persons at high risk who should not be vaccinated.
Chemoprophylaxis also can be offered to persons who wish
to avoid influenza illness. Health-care providers and patients
should make this decision on an individual basis.
Control of Influenza Outbreaks in Institutions
Using antiviral drugs for treatment and chemoprophylaxis
of influenza is a key component of influenza outbreak con-
trol in institutions. In addition to antiviral medications, other
outbreak-control measures include instituting droplet precau-
tions and establishing cohorts of patients with confirmed or
suspected influenza, reoffering influenza vaccinations to un-
vaccinated staff and patients, restricting staff movement be-
tween wards or buildings, and restricting contact between ill
staff or visitors and patients (359–361) (see Additional Infor-
mation Regarding Influenza Virus Infection Control Among
Specific Populations).
The majority of published reports concerning use of anti-
viral agents to control influenza outbreaks in institutions are
based on studies of influenza A outbreaks among nursing home
populations that received amantadine or rimantadine
(335,362–366). Less information is available concerning use
of neuraminidase inhibitors in influenza A or B institutional
outbreaks (337,338,344,357,367). When confirmed or sus-
pected outbreaks of influenza occur in institutions that house
persons at high risk, chemoprophylaxis should be started as
early as possible to reduce the spread of the virus. In these
situations, having preapproved orders from physicians or plans
to obtain orders for antiviral medications on short notice can
substantially expedite administration of antiviral medications.
When outbreaks occur in institutions, chemoprophylaxis
should be administered to all residents, regardless of whether
they received influenza vaccinations during the previous fall,
and should continue for a minimum of 2 weeks. If surveil-
lance indicates that new cases continue to occur, chemopro-
phylaxis should be continued until approximately 1 week after
the end of the outbreak. The dosage for each resident should
be determined individually. Chemoprophylaxis also can be
offered to unvaccinated staff members who provide care to
persons at high risk. Chemoprophylaxis should be consid-
ered for all employees, regardless of their vaccination status,
if the outbreak is suspected to be caused by a strain of influ-
enza virus that is not well-matched to the vaccine.
In addition to nursing homes, chemoprophylaxis also can
be considered for controlling influenza outbreaks in other
closed or semiclosed settings (e.g., dormitories or other set-
tings in which persons live in close proximity).
To limit the potential transmission of drug-resistant virus
during outbreaks in institutions, whether in chronic or acute-
care settings or other closed settings, measures should be taken
to reduce contact as much as possible between persons taking
antiviral drugs for treatment and other persons, including
those taking chemoprophylaxis (see Antiviral Drug-Resistant
Strains of Influenza Virus).
Dosage
Dosage recommendations vary by age group and medical
conditions (Table 6).
Children
Zanamivir. Zanamivir is approved for treatment of influ-
enza among children aged >7 years. The recommended dos-
age of zanamivir for treatment of influenza is two inhalations
(one 5-mg blister per inhalation for a total dose of 10 mg)
twice daily (approximately 12 hours apart); the chemopro-
phylaxis dosage of zanamivir for children aged >5 years is 10
mg (two inhalations) once a day (317).
Oseltamivir. Oseltamivir is approved for treatment and
chemoprophylaxis among persons aged >1 year. Recom-
mended treatment and chemoprophylaxis dosages of
oseltamivir for children vary by the weight of the child. The
treatment dosage recommendation of oseltamivir for children
who weigh <15 kg is 30 mg twice a day; for children weigh-
ing >15–23 kg, 45 mg twice a day; for those weighing >23–
40 kg, 60 mg twice a day; and for children weighing >40 kg,
75 mg twice a day (310). The chemoprophylaxis recom-
mended dosage of oseltamivir for children weighing <15 kg
is 30 mg once a day; for those weighing >15–23 kg, 45 mg
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once a day; for those weighing >23–40 kg, 60 mg once a day;
and for those weighing >40 kg, 75 mg once a day.
Persons Aged >65 Years
Zanamivir and Oseltamivir. No reduction in dosage is
recommended on the basis of age alone.
Persons with Impaired Renal Function
Zanamivir. Limited data are available regarding the safety
and efficacy of zanamivir for patients with impaired renal func-
tion. Among patients with renal failure who were adminis-
tered a single intravenous dose of zanamivir, decreases in renal
clearance, increases in half-life, and increased systemic expo-
sure to zanamivir were observed (317,368). However, a lim-
ited number of healthy volunteers who received high doses of
zanamivir intravenously tolerated systemic levels of zanamivir
that were substantially higher than those resulting from ad-
ministration of zanamivir by oral inhalation at the recom-
mended dose (369,370). On the basis of these considerations,
the manufacturer recommends no dose adjustment for in-
haled zanamivir for a 5-day course of treatment for patients
with either mild-to-moderate or severe impairment in renal
function (317).
Oseltamivir. Serum concentrations of oseltamivir carboxy-
late, the active metabolite of oseltamivir, increase with de-
clining renal function (310,371). For patients with creatinine
clearance of 10–30 mL/min (310), a reduction of the treat-
ment dosage of oseltamivir to 75 mg once daily and in the
chemoprophylaxis dosage to 75 mg every other day is recom-
mended. No treatment or chemoprophylaxis dosing recom-
mendations are available for patients undergoing routine renal
dialysis treatment.
Persons with Liver Disease
Zanamivir and Oseltamivir. Neither of these medications
has been studied among persons with hepatic dysfunction.
Persons with Seizure Disorders
Zanamivir and Oseltamivir. Seizure events have been re-
ported during postmarketing use of zanamivir and oseltamivir,
although no epidemiologic studies have reported any increased
risk for seizures with either zanamivir or oseltamivir use.
Route
Oseltamivir is administered orally in capsule or oral suspen-
sion form. Zanamivir is available as a dry powder that is self-
administered via oral inhalation by using a plastic device included
in the package with the medication. Patients will benefit from
instruction and demonstration of correct use of this device.
TABLE 6. Recommended daily dosage of influenza antiviral medications for treatment and chemoprophylaxis — United States
Age group (yrs)
Antiviral agent 1–6 7–9 10–12 13–64 >65
Zanamivir*
Treatment, N/A† 10 mg (two 10 mg (two 10 mg (two 10 mg (two
influenza A and B inhalations) inhalations) twice inhalations) inhalations)
twice daily twice daily twice daily twice daily
Chemoprophylaxis, Ages 1–4 Ages 5–9 10 mg (two 10 mg (two 10 mg (two
influenza A and B N/A† 10 mg (two inhalations) inhalations) inhalations)
inhalations) once daily once daily once daily
once daily
Oseltamivir
Treatment,§ Dose varies by Dose varies by Dose varies by 75 mg twice daily 75 mg twice daily
influenza A and B child’s weight¶ child’s weight¶ child’s weight¶
Chemoprophylaxis, Dose varies by Dose varies by Dose varies by 75 mg once daily 75 mg once daily
influenza A and B child’s weight** child’s weight** child’s weight**
NOTE: Zanamivir is manufactured by GlaxoSmithKline (Relenza® — inhaled powder). Oseltamivir is manufactured by Roche Pharmaceuticals (Tamiflu® —
tablet). This information is based on data published by the Food and Drug Administration (FDA), which is available at http://www.fda.gov.
* Zanamivir is administered through oral inhalation by using a plastic device included in the medication package. Patients will benefit from instruction and
demonstration of the correct use of the device. Zanamivir is not recommended for those persons with underlying airway disease.
† Not applicable.
§ A reduction in the dose of oseltamivir is recommended for persons with creatinine clearance <30 mL/min.
¶ The treatment dosing recommendations of oseltamivir for children weighing <15 kg is 30 mg twice a day; for children weighing >15–23 kg, the dose is 45
mg twice a day; for children weighing >23–40 kg, the dose is 60 mg twice a day; and for children weighing >40 kg, the dose is 75 mg twice a day.
**The chemoprophylaxis dosing recommendations of oseltamivir for children weighing <15 kg is 30 mg once a day; for children weighing >15–23 kg, the dose
is 45 mg once a day; for children weighing >23–40 kg, the dose is 60 mg once a day; and for children >40 kg, the dose is 75 mg once a day.
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Pharmacokinetics
Zanamivir
In studies of healthy volunteers, approximately 7%–21% of
the orally inhaled zanamivir dose reached the lungs, and 70%–
87% was deposited in the oropharynx (317,372). Approxi-
mately 4%–17% of the total amount of orally inhaled zanamivir
is systemically absorbed. Systemically absorbed zanamivir has
a half-life of 2.5–5.1 hours and is excreted unchanged in the
urine. Unabsorbed drug is excreted in the feces (317,370).
Oseltamivir
Approximately 80% of orally administered oseltamivir is
absorbed systemically (371). Absorbed oseltamivir is metabo-
lized to oseltamivir carboxylate, the active neuraminidase in-
hibitor, primarily by hepatic esterases. Oseltamivir carboxylate
has a half-life of 6–10 hours and is excreted in the urine by
glomerular filtration and tubular secretion via the anionic
pathway (310,373). Unmetabolized oseltamivir also is excreted
in the urine by glomerular filtration and tubular secretion
(325).
Side Effects and Adverse Reactions
When considering use of influenza antiviral medications
(i.e., choice of antiviral drug, dosage, and duration of therapy),
clinicians must consider the patient’s age, weight, and renal
function (Table 6); presence of other medical conditions; in-
dications for use (i.e., chemoprophylaxis or treatment); and
the potential for interaction with other medications.
Zanamivir
In a study of zanamivir treatment of ILI among persons
with asthma or chronic obstructive pulmonary disease where
study medication was administered after use of a B2-agonist,
13% of patients receiving zanamivir and 14% of patients who
received placebo (inhaled powdered lactose vehicle) experi-
enced a >20% decline in forced expiratory volume in 1 sec-
ond (FEV1) after treatment (317,330). However, in a phase I
study of persons with mild or moderate asthma who did not
have ILI, one of 13 patients experienced bronchospasm after
administration of zanamivir (317). In addition, during
postmarketing surveillance, cases of respiratory function de-
terioration after inhalation of zanamivir have been reported.
Certain patients had underlying airway disease (e.g., asthma
or chronic obstructive pulmonary disease). Because of the risk
for serious adverse events and because the efficacy has not
been demonstrated among this population, zanamivir is not
recommended for treatment for patients with underlying air-
way disease (317). If physicians decide to prescribe zanamivir
to patients with underlying chronic respiratory disease after
carefully considering potential risks and benefits, the drug
should be used with caution under conditions of appropriate
monitoring and supportive care, including the availability of
short-acting bronchodilators (355). Patients with asthma or
chronic obstructive pulmonary disease who use zanamivir are
advised to 1) have a fast-acting inhaled bronchodilator avail-
able when inhaling zanamivir and 2) stop using zanamivir
and contact their physician if they experience difficulty breath-
ing (317). No definitive evidence is available regarding the
safety or efficacy of zanamivir for persons with underlying
respiratory or cardiac disease or for persons with complica-
tions of acute influenza (355). Allergic reactions, including
oropharyngeal or facial edema, also have been reported dur-
ing postmarketing surveillance (317,337).
In clinical treatment studies of persons with uncomplicated
influenza, the frequencies of adverse events were similar for
persons receiving inhaled zanamivir and for those receiving pla-
cebo (i.e., inhaled lactose vehicle alone) (320–325,337). The
most common adverse events reported by both groups were
diarrhea; nausea; sinusitis; nasal signs and symptoms; bronchi-
tis; cough; headache; dizziness; and ear, nose, and throat infec-
tions. Each of these symptoms was reported by <5% of persons
in the clinical treatment studies combined (317).
Oseltamivir
Nausea and vomiting were reported more frequently among
adults receiving oseltamivir for treatment (nausea without
vomiting, approximately 10%; vomiting, approximately 9%)
than among persons receiving placebo (nausea without vom-
iting, approximately 6%; vomiting, approximately 3%)
(310,326,327,374). Among children treated with oseltamivir,
14% had vomiting, compared with 8.5% of placebo recipi-
ents. Overall, 1% discontinued the drug secondary to this
side effect (329), whereas a limited number of adults who
were enrolled in clinical treatment trials of oseltamivir dis-
continued treatment because of these symptoms (310). Simi-
lar types and rates of adverse events were reported in studies
of oseltamivir chemoprophylaxis (310). Nausea and vomit-
ing might be less severe if oseltamivir is taken with food
(317,310).
Use During Pregnancy
No clinical studies have been conducted regarding the safety
or efficacy of zanamivir or oseltamivir for pregnant women.
Because of the unknown effects of influenza antiviral drugs
on pregnant women and their fetuses, these two drugs should
be used during pregnancy only if the potential benefit justi-
fies the potential risk to the embryo or fetus. Oseltamivir and
zanamivir are both “Pregnancy Category C” medications (see
manufacturers’ package inserts) (317,375).
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Drug Interactions
Clinical data are limited regarding drug interactions with
zanamivir. However, no known drug interactions have been
reported, and no clinically critical drug interactions have been
predicted on the basis of in vitro data and data from studies
using rats (310,373).
Limited clinical data are available regarding drug interac-
tions with oseltamivir. Because oseltamivir and oseltamivir
carboxylate are excreted in the urine by glomerular filtration
and tubular secretion via the anionic pathway, a potential ex-
ists for interaction with other agents excreted by this path-
way. For example, coadministration of oseltamivir and
probenecid resulted in reduced clearance of oseltamivir car-
boxylate by approximately 50% and a corresponding approxi-
mate twofold increase in the plasma levels of oseltamivir
carboxylate (304,367).
No published data are available concerning the safety or
efficacy of using combinations of any of these influenza anti-
viral drugs. For more detailed information concerning po-
tential drug interactions for any of these influenza antiviral
drugs, package inserts should be consulted.
Information Regarding the Vaccines
for Children Program
 The Vaccines for Children (VFC) program supplies vac-
cine to all states, territories, and the District of Columbia for
use by participating providers. These vaccines are to be ad-
ministered to eligible children without vaccine cost to the pa-
tient, as well as the provider. All routine childhood vaccines
recommended by ACIP are available through this program.
The program saves parents and providers out-of-pocket ex-
penses for vaccine purchases and provides cost-savings to states
through the CDC vaccine contracts. The program results in
lower vaccine prices and assures that all states pay the same
contract prices. Detailed information regarding the VFC pro-
gram is available at http://www.cdc.gov/nip/vfc/default.htm.
Sources of Information Regarding
Influenza and Its Surveillance
Information regarding influenza surveillance, prevention,
detection, and control is available at http://www.cdc.gov/flu/
weekly/fluactivity.htm. Surveillance information is available
through the CDC Voice Information System (influenza up-
date) at 888-232-3228 or CDC Fax Information Service at
888-232-3299. During October–May, surveillance informa-
tion is updated weekly. In addition, periodic updates regard-
ing influenza are published in the MMWR Weekly Report
(http://www.cdc.gov/mmwr). Additional information regard-
ing influenza vaccine can be obtained by calling 800-CDC-
INFO (800-232-4636). State and local health departments
should be consulted concerning availability of influenza vac-
cine, access to vaccination programs, information related to
state or local influenza activity, reporting of influenza out-
breaks and influenza-related pediatric deaths, and advice con-
cerning outbreak control.
Reporting of Adverse Events
Following Vaccination
Clinically significant adverse events that follow vaccination
should be reported through VAERS at http://vaers.hhs.gov
or by calling the 24-hour national toll-free hotline at
800-822-7967.
Additional Information Regarding
Influenza Virus Infection Control
Among Specific Populations
Each year, ACIP provides general, annually updated infor-
mation regarding control and prevention of influenza. Other
reports related to controlling and preventing influenza among
specific populations (e.g., immunocompromised persons,
health-care workers, hospital patients, pregnant women, chil-
dren, and travelers) also are available in the following
publications:
• American Academy of Pediatrics. 2006 red book: report
of the Committee on Infectious Diseases. 27th ed. Elk
Grove Village, IL: American Academy of Pediatrics; 2006.
• American College of Obstetricians and Gynecologists.
Influenza vaccination and treatment during pregnancy.
ACOG committee opinion no. 305. Obstet Gynecol
2004;104:1125–6.
• Bodnar UR, Maloney SA, Fielding KL, et al. Preliminary
guidelines for the prevention and control of influenza-
like illness among passengers and crew members on cruise
ships. Atlanta, GA: US Department of Health and Hu-
man Services, CDC, National Center for Infectious Dis-
eases; 1999.
• Bradley SF. The Long-Term–Care Committee of the So-
ciety for Health-care Epidemiology of America. Preven-
tion of influenza in long-term care facilities. Infect Control
Hosp Epidemiol 1999;20:629–37.
• CDC. Influenza vaccination of health-care personnel:
recommendations of the Healthcare Infection Control
Practices Advisory Committee (HICPAC) and the Advi-
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sory Committee on Immunization Practices (ACIP).
MMWR 2006;55(No. RR-2).
• CDC. Recommended adult immunization schedule—
United States, October 2005–September 2006. MMWR
2005;54:Q1–4.
• CDC. Guidelines for preventing health-care–associated
pneumonia, 2003: recommendations of CDC and the
Health-care Infection Control Practices Advisory Com-
mittee. MMWR 2003;53(No. RR-3).
• CDC. Respiratory hygiene/cough etiquette in healthcare
settings. Atlanta, GA: US Department of Health and
Human Services, CDC; 2003. Available at http://
www.cdc.gov/flu/professionals/infectioncontrol/
resphygiene.htm.
• CDC. Prevention of specific infectious diseases [Chapter
4]. In: Travelers’ Health: Yellow Book. Health informa-
tion for international travel, 2005–2006. Atlanta, GA:
US Department of Health and Human Services, CDC;
2006. Available at http://www2.ncid.cdc.gov/travel/yb/
utils/ybGet.asp?section=dis&obj=influenza.htm.
• CDC. General recommendations on immunization: rec-
ommendations of the Advisory Committee on Immuni-
zation Practices (ACIP) and the American Academy of
Family Physicians (AAFP). MMWR 2002;51(No.
RR-2).
• CDC. Detection and control of influenza outbreaks in
acute care facilities. Atlanta, GA: US Department of
Health and Human Services, CDC, National Center for
Infections Diseases; 2001.
• Garner JS, Hospital Infection Control Practices Advisory
Committee. Guideline for isolation precautions in hos-
pitals. Infect Control Hosp Epidemiol 1996;17:53–80.
• Sneller V-P, Izurieta H, Bridges C, et al. Prevention and
control of vaccine-preventable diseases in long-term care
facilities. Journal of the American Medical Directors As-
sociation 2000;1(Suppl):S2–37.
• US Public Health Service (USPHS) and Infectious Dis-
eases Society of America (IDSA). USPHS/IDSA Preven-
tion of Opportunistic Infections Working Group. 2001
USPHS/IDSA guidelines for the prevention of opportu-
nistic infections in persons infected with human immu-
nodeficiency virus. Final November 28, 2001:1–65.
Available at http://www.aidsinfo.nih.gov.
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